<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id>
<journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id>
<journal-id journal-id-type="publisher-id">ijms</journal-id>
<journal-title-group>
<journal-title>International Journal of Molecular Sciences</journal-title>
</journal-title-group>
<issn pub-type="epub">1422-0067</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31344835</article-id>
<article-id pub-id-type="pmc">6695947</article-id>
<article-id pub-id-type="doi">10.3390/ijms20153614</article-id>
<article-id pub-id-type="publisher-id">ijms-20-03614</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Clinical Therapeutic Strategy and Neuronal Mechanism Underlying Post-Traumatic Stress Disorder (PTSD)</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Yabuki</surname>
<given-names>Yasushi</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8526-2824</contrib-id>
<name>
<surname>Fukunaga</surname>
<given-names>Kohji</given-names>
</name>
<xref ref-type="corresp" rid="c1-ijms-20-03614">*</xref>
</contrib>
</contrib-group>
<aff id="af1-ijms-20-03614">Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan</aff>
<author-notes>
<corresp id="c1-ijms-20-03614"><label>*</label>Correspondence: <email>kfukunaga@m.tohoku.ac.jp</email>; Tel.: +81-22-795-6836; Fax: +81-22-795-683</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>24</day>
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<month>8</month>
<year>2019</year>
</pub-date>
<volume>20</volume>
<issue>15</issue>
<elocation-id>3614</elocation-id>
<history>
<date date-type="received">
<day>10</day>
<month>7</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>7</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© 2019 by the authors.</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Post-traumatic stress disorder (PTSD) is characterized by an exaggerated response to contextual memory and impaired fear extinction, with or without mild cognitive impairment, learning deficits, and nightmares. PTSD is often developed by traumatic events, such as war, terrorist attack, natural calamities, etc. Clinical and animal studies suggest that aberrant susceptibility of emotion- and fear-related neurocircuits, including the amygdala, prefrontal cortex (PFC), and hippocampus may contribute to the development and retention of PTSD symptoms. Psychological and pharmacological therapy, such as cognitive behavioral therapy (CBT), and treatment with anti-depressive agents and/or antipsychotics significantly attenuate PTSD symptoms. However, more effective therapeutics are required for improvement of quality of life in PTSD patients. Previous studies have reported that ω3 long-chain polyunsaturated fatty acid (LCPUFA) supplements can suppress the development of PTSD symptoms. Fatty acid binding proteins (FABPs) are essential for LCPUFA intracellular trafficking. In this review, we have introduced <italic>Fabp3</italic> null mice as an animal model of PTSD with impaired fear extinction. Moreover, we have addressed the neuronal circuits and novel therapeutic strategies for PTSD symptoms.</p>
</abstract>
<kwd-group>
<kwd>post-traumatic stress disorder</kwd>
<kwd>fatty acid binding protein 3</kwd>
<kwd>calcium/calmodulin-dependent protein kinase II</kwd>
<kwd>ramelteon</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-ijms-20-03614" sec-type="intro">
<title>1. Introduction</title>
<p>Post-traumatic stress disorder (PTSD), a profound public health issue, is most often induced by distressing events. During a lifetime, a majority of the population, 60.7% of men and 51.2% of women, may be exposed to traumatic events that have the potential to trigger the development of PTSD [<xref ref-type="bibr" rid="B1-ijms-20-03614">1</xref>,<xref ref-type="bibr" rid="B2-ijms-20-03614">2</xref>]. While previous studies have estimated the lifetime prevalence of PTSD in United State as 6.1–6.8%, and in Japan as 1.3% [<xref ref-type="bibr" rid="B3-ijms-20-03614">3</xref>,<xref ref-type="bibr" rid="B4-ijms-20-03614">4</xref>,<xref ref-type="bibr" rid="B5-ijms-20-03614">5</xref>], 16.7% of the individuals exposed to the terrorist attack of September 11, 2001, experienced an onset of PTSD [<xref ref-type="bibr" rid="B6-ijms-20-03614">6</xref>]. In addition, 5.7% of the survivors from the tsunami caused by The Great East Japan Earthquake on March 11 showed post-traumatic stress reactions [<xref ref-type="bibr" rid="B7-ijms-20-03614">7</xref>]. Development and retention of PTSD are observed not only in the victims of disasters, but also in the rescue workers [<xref ref-type="bibr" rid="B8-ijms-20-03614">8</xref>,<xref ref-type="bibr" rid="B9-ijms-20-03614">9</xref>,<xref ref-type="bibr" rid="B10-ijms-20-03614">10</xref>]. In the pathogenesis of PTSD, the fear memories are aberrantly consolidated, while the fear extinction fails to function [<xref ref-type="bibr" rid="B11-ijms-20-03614">11</xref>]. Impaired fear memory consolidation and extinction triggers develop nightmares and flashbacks in patients with PTSD [<xref ref-type="bibr" rid="B2-ijms-20-03614">2</xref>,<xref ref-type="bibr" rid="B11-ijms-20-03614">11</xref>,<xref ref-type="bibr" rid="B12-ijms-20-03614">12</xref>]. Patients with PTSD often show cognitive impairment, attention and/or learning deficits [<xref ref-type="bibr" rid="B13-ijms-20-03614">13</xref>,<xref ref-type="bibr" rid="B14-ijms-20-03614">14</xref>], which reduce the quality of life (QOL). According to clinical and animal studies, emotion- and fear-associated neuronal circuits are related to the development and retention of PTSD symptoms [<xref ref-type="bibr" rid="B11-ijms-20-03614">11</xref>,<xref ref-type="bibr" rid="B15-ijms-20-03614">15</xref>,<xref ref-type="bibr" rid="B16-ijms-20-03614">16</xref>] and several therapeutics have been recommended [<xref ref-type="bibr" rid="B1-ijms-20-03614">1</xref>,<xref ref-type="bibr" rid="B12-ijms-20-03614">12</xref>,<xref ref-type="bibr" rid="B17-ijms-20-03614">17</xref>,<xref ref-type="bibr" rid="B18-ijms-20-03614">18</xref>]. However, mechanisms underlying enhanced susceptibility to impaired fear memory consolidation and extinction are not clear, and therefore, there are limited effective therapeutic approaches.</p>
<p>We, here in this review, discuss the neuronal circuits and a novel therapeutic strategy for PTSD symptoms. Moreover, we introduce a PTSD animal model to evaluate the efficacy of therapeutics in future investigations.</p>
</sec>
<sec id="sec2-ijms-20-03614">
<title>2. Neuronal Circuits in PTSD Symptoms</title>
<p>Animal studies suggest the crucial brain regions associated with PTSD symptoms as the prefrontal cortex (PFC), anterior cingulated cortex (ACC), amygdala, and the hippocampus, which are involved in the formation and retrieval of emotional and fear memory [<xref ref-type="bibr" rid="B19-ijms-20-03614">19</xref>,<xref ref-type="bibr" rid="B20-ijms-20-03614">20</xref>,<xref ref-type="bibr" rid="B21-ijms-20-03614">21</xref>]. Destruction of the medial PFC (mPFC) by electrolytic lesion has shown to impair recall of fear extinction in rats [<xref ref-type="bibr" rid="B22-ijms-20-03614">22</xref>]. The elevated neuronal firing rate in the infralimbic mPFC has been correlated with spontaneous recovery of freezing after the fear extinction, and short-term electric stimuli in infralimbic mPFC has shown to facilitate fear extinction memory in rats [<xref ref-type="bibr" rid="B19-ijms-20-03614">19</xref>]. The infusion of γ-aminobutyric acid (GABA) receptor agonist, muscimol, into rat amygdala fails to acquire and consolidate fear memory [<xref ref-type="bibr" rid="B21-ijms-20-03614">21</xref>]. Pharmacological lesions and inactivation in rat hippocampus have shown to block contextual fear memory formation [<xref ref-type="bibr" rid="B23-ijms-20-03614">23</xref>,<xref ref-type="bibr" rid="B24-ijms-20-03614">24</xref>]. Moreover, these brain regions are connected and regulated with each other [<xref ref-type="bibr" rid="B20-ijms-20-03614">20</xref>,<xref ref-type="bibr" rid="B25-ijms-20-03614">25</xref>,<xref ref-type="bibr" rid="B26-ijms-20-03614">26</xref>]. In another study, the inactivation of basolateral amygdala (BLA) by infusion of muscimol decreased the neuronal activity in pyramidal neurons, as well as the fear conditioning tone response in rat prelimbic mPFC. Inversely, the inhibited ventral hippocampal activity enhanced the activity of interneurons and then promoted the tone response in rat prelimbic mPFC [<xref ref-type="bibr" rid="B25-ijms-20-03614">25</xref>]. Optogenetic analyses have also indicated that the mouse BLA-mPFC synaptic inhibition impairs fear memory retention and facilitates fear extinction [<xref ref-type="bibr" rid="B27-ijms-20-03614">27</xref>]. Therefore, neuronal connections between PFC, amygdala, and hippocampus may have an essential role in normal fear consolidation and extinction.</p>
<p>In addition, human studies also support the above discussed neuronal circuit in PTSD patients. The magnetic resonance imaging (MRI) studies have demonstrated reduced volumes of hippocampus and ACC in the brain of PTSD patients [<xref ref-type="bibr" rid="B28-ijms-20-03614">28</xref>,<xref ref-type="bibr" rid="B29-ijms-20-03614">29</xref>,<xref ref-type="bibr" rid="B30-ijms-20-03614">30</xref>,<xref ref-type="bibr" rid="B31-ijms-20-03614">31</xref>,<xref ref-type="bibr" rid="B32-ijms-20-03614">32</xref>]. Functional MRI researches have also defined excessive activity in the amygdala, while hypofunction in both the mPFC and ACC in patients with PTSD when they are exposed to fear condition [<xref ref-type="bibr" rid="B33-ijms-20-03614">33</xref>,<xref ref-type="bibr" rid="B34-ijms-20-03614">34</xref>,<xref ref-type="bibr" rid="B35-ijms-20-03614">35</xref>,<xref ref-type="bibr" rid="B36-ijms-20-03614">36</xref>,<xref ref-type="bibr" rid="B37-ijms-20-03614">37</xref>]. In contrast, several groups have reported that the activities of both the amygdala and ACC are higher in patients with PTSD than that in healthy subjects [<xref ref-type="bibr" rid="B38-ijms-20-03614">38</xref>,<xref ref-type="bibr" rid="B39-ijms-20-03614">39</xref>]; thus, the neuronal activity of ACC in PTSD is controversial. Brain blood flow is significantly decreased in the mPFC of patients with PTSD exposed to traumatic stimuli, whereas in non-PTSD subjects, it is elevated in ACC, indicating a negative relationship between mPFC and ACC [<xref ref-type="bibr" rid="B31-ijms-20-03614">31</xref>,<xref ref-type="bibr" rid="B40-ijms-20-03614">40</xref>]. In addition, synchronous neuronal activities between ACC and BLA are essential for a normal fear response [<xref ref-type="bibr" rid="B41-ijms-20-03614">41</xref>,<xref ref-type="bibr" rid="B42-ijms-20-03614">42</xref>]. Previous reports suggest that neuronal activities in the PFC, including mPFC and ACC, negatively function in BLA, thereby suppressing exacerbated fear response and anxiety [<xref ref-type="bibr" rid="B43-ijms-20-03614">43</xref>,<xref ref-type="bibr" rid="B44-ijms-20-03614">44</xref>,<xref ref-type="bibr" rid="B45-ijms-20-03614">45</xref>]. According to clinical therapy reports, veterans with PTSD, who had been deployed to Iraq or Afghanistan, either showed improvement or normalization of the hyperactive amygdala and hypofunctional ACC on exposure therapy among individuals with PTSD during an affective Stroop response test [<xref ref-type="bibr" rid="B46-ijms-20-03614">46</xref>,<xref ref-type="bibr" rid="B47-ijms-20-03614">47</xref>]. Oxytocin treatment alleviates the impairment of the working memory, and concomitantly increases connectivity between the dorsolateral PFC and ACC in patients with PTSD [<xref ref-type="bibr" rid="B48-ijms-20-03614">48</xref>]. Moreover, both pharmacological and psychological therapies have been reported to increase the volumes of the hippocampus and/or ACC, in association with the improvement of PTSD symptoms [<xref ref-type="bibr" rid="B49-ijms-20-03614">49</xref>,<xref ref-type="bibr" rid="B50-ijms-20-03614">50</xref>,<xref ref-type="bibr" rid="B51-ijms-20-03614">51</xref>,<xref ref-type="bibr" rid="B52-ijms-20-03614">52</xref>,<xref ref-type="bibr" rid="B53-ijms-20-03614">53</xref>]. Taken together, these observations suggest that aberrant neuronal activities in PFC, ACC, amygdala, and hippocampus may be one of the reasons underlying development and retention of PTSD symptoms.</p>
</sec>
<sec id="sec3-ijms-20-03614">
<title>3. Clinical Therapeutics for Patients with PTSD</title>
<sec id="sec3dot1-ijms-20-03614">
<title>3.1. Psychological Therapy for PTSD Symptoms</title>
<p>According to National Institute for Clinical Excellence study (2005), Kar (2011) and Lee et al. (2016), psychological therapies, such as cognitive behavioral therapy (CBT) are recommended as the first-line therapy for PTSD symptoms [<xref ref-type="bibr" rid="B54-ijms-20-03614">54</xref>,<xref ref-type="bibr" rid="B55-ijms-20-03614">55</xref>,<xref ref-type="bibr" rid="B56-ijms-20-03614">56</xref>]. CBTs, as represented by cognitive processing therapy, stress inoculation training, and written exposure therapy significantly improve PTSD symptoms [<xref ref-type="bibr" rid="B18-ijms-20-03614">18</xref>,<xref ref-type="bibr" rid="B57-ijms-20-03614">57</xref>,<xref ref-type="bibr" rid="B58-ijms-20-03614">58</xref>,<xref ref-type="bibr" rid="B59-ijms-20-03614">59</xref>,<xref ref-type="bibr" rid="B60-ijms-20-03614">60</xref>,<xref ref-type="bibr" rid="B61-ijms-20-03614">61</xref>]. Eye movement desensitization and reprocessing also attenuates PTSD symptoms [<xref ref-type="bibr" rid="B18-ijms-20-03614">18</xref>,<xref ref-type="bibr" rid="B62-ijms-20-03614">62</xref>,<xref ref-type="bibr" rid="B63-ijms-20-03614">63</xref>,<xref ref-type="bibr" rid="B64-ijms-20-03614">64</xref>]. The other types of psychological therapy highlight the effectiveness of imagery rehearsal therapy (IRT) and Seeking Safety (SS) in PTSD symptoms. However, supporting evidence for such therapies are inconclusive [<xref ref-type="bibr" rid="B18-ijms-20-03614">18</xref>,<xref ref-type="bibr" rid="B65-ijms-20-03614">65</xref>,<xref ref-type="bibr" rid="B66-ijms-20-03614">66</xref>]. PTSD subjects undergoing CBTs have demonstrated better QOL before the treatment [<xref ref-type="bibr" rid="B61-ijms-20-03614">61</xref>,<xref ref-type="bibr" rid="B67-ijms-20-03614">67</xref>]. On the other hand, no differences in QOL have been observed between pre- and post-treatment with eye movement desensitization and reprocessing in patients with PTSD [<xref ref-type="bibr" rid="B18-ijms-20-03614">18</xref>,<xref ref-type="bibr" rid="B62-ijms-20-03614">62</xref>].</p>
</sec>
<sec id="sec3dot2-ijms-20-03614">
<title>3.2. Pharmacological Therapy for PTSD Symptoms</title>
<p>Since imperative traumatic incidents, such as the terrorist attack and massive earthquake occur unexpectedly, and possess a strong potential to develop PTSD in the victims [<xref ref-type="bibr" rid="B6-ijms-20-03614">6</xref>,<xref ref-type="bibr" rid="B7-ijms-20-03614">7</xref>], pharmacological therapies are also crucial for the relief of PTSD symptoms. Clinical studies have demonstrated an improvement in PTSD by selective serotonin reuptake inhibitors (SSRIs), serotonin and noradrenaline reuptake inhibitor (SNRI), antipsychotics, and other drugs as listed in <xref ref-type="table" rid="ijms-20-03614-t001">Table 1</xref>. SSRIs, such as fluoxetine, paroxetine, and sertraline significantly relieve PTSD symptoms and partially improve QOL in the PTSD subjects [<xref ref-type="bibr" rid="B64-ijms-20-03614">64</xref>,<xref ref-type="bibr" rid="B68-ijms-20-03614">68</xref>,<xref ref-type="bibr" rid="B69-ijms-20-03614">69</xref>,<xref ref-type="bibr" rid="B70-ijms-20-03614">70</xref>,<xref ref-type="bibr" rid="B71-ijms-20-03614">71</xref>,<xref ref-type="bibr" rid="B72-ijms-20-03614">72</xref>,<xref ref-type="bibr" rid="B73-ijms-20-03614">73</xref>,<xref ref-type="bibr" rid="B74-ijms-20-03614">74</xref>,<xref ref-type="bibr" rid="B75-ijms-20-03614">75</xref>,<xref ref-type="bibr" rid="B76-ijms-20-03614">76</xref>]. Treatment with SNRI, venlafaxine, also attenuates the PTSD symptoms and shows improvement in QOL [<xref ref-type="bibr" rid="B76-ijms-20-03614">76</xref>,<xref ref-type="bibr" rid="B77-ijms-20-03614">77</xref>]. The effects of another type of antidepressants on PTSD symptoms are relatively weaker than those of SSRI and SNRI [<xref ref-type="bibr" rid="B78-ijms-20-03614">78</xref>,<xref ref-type="bibr" rid="B79-ijms-20-03614">79</xref>,<xref ref-type="bibr" rid="B80-ijms-20-03614">80</xref>,<xref ref-type="bibr" rid="B81-ijms-20-03614">81</xref>]. Atypical antipsychotics risperidone, olanzapine, and aripiprazole have also been effective for PTSD symptoms (<xref ref-type="table" rid="ijms-20-03614-t001">Table 1</xref>) [<xref ref-type="bibr" rid="B82-ijms-20-03614">82</xref>,<xref ref-type="bibr" rid="B83-ijms-20-03614">83</xref>,<xref ref-type="bibr" rid="B84-ijms-20-03614">84</xref>,<xref ref-type="bibr" rid="B85-ijms-20-03614">85</xref>,<xref ref-type="bibr" rid="B86-ijms-20-03614">86</xref>,<xref ref-type="bibr" rid="B87-ijms-20-03614">87</xref>]; however, evidence for their therapeutic potential is limited [<xref ref-type="bibr" rid="B18-ijms-20-03614">18</xref>]. Importantly, risperidone and olanzapine relieve the PTSD symptoms that are resistant to SSRI treatment [<xref ref-type="bibr" rid="B84-ijms-20-03614">84</xref>,<xref ref-type="bibr" rid="B86-ijms-20-03614">86</xref>]. The efficacies of calcium channel blocker, alpha blocker, anticonvulsant, and synthetic cannabinoid on PTSD symptoms have also been reported (<xref ref-type="table" rid="ijms-20-03614-t001">Table 1</xref>) [<xref ref-type="bibr" rid="B88-ijms-20-03614">88</xref>,<xref ref-type="bibr" rid="B89-ijms-20-03614">89</xref>,<xref ref-type="bibr" rid="B90-ijms-20-03614">90</xref>,<xref ref-type="bibr" rid="B91-ijms-20-03614">91</xref>,<xref ref-type="bibr" rid="B92-ijms-20-03614">92</xref>,<xref ref-type="bibr" rid="B93-ijms-20-03614">93</xref>,<xref ref-type="bibr" rid="B94-ijms-20-03614">94</xref>]. However, only paroxetine and sertraline have been approved by the U.S. Food and Drug Administration (FDA) for PTSD therapy [<xref ref-type="bibr" rid="B18-ijms-20-03614">18</xref>], and these pharmacological treatments are extremely limited, due to their side effects. Therefore, more safe and effective therapeutics for PTSD are required.</p>
</sec>
</sec>
<sec id="sec4-ijms-20-03614">
<title>4. Animal Models of PTSD</title>
<p>PTSD animal models are essential to evaluate the efficacy of drugs and to reveal the neurochemical basis underlying the development and retention of PTSD. Stress-induced animal models have been proposed as PTSD models in various studies [<xref ref-type="bibr" rid="B110-ijms-20-03614">110</xref>,<xref ref-type="bibr" rid="B111-ijms-20-03614">111</xref>]. Rats subjected to electric stimulations from two different contexts show an exacerbated sensitization of the fear response [<xref ref-type="bibr" rid="B110-ijms-20-03614">110</xref>]. Single prolonged stress (SPS) combined with restraint for 2 h, forced swimming for 20 min, and exposure to ether anesthesia has shown to induce hypersensitivity of glucocorticoid negative feedback with abnormalities in hypothalamic-pituitary-adrenal (HPA) axis in male rats, similar to that of patients with PTSD [<xref ref-type="bibr" rid="B111-ijms-20-03614">111</xref>]. Studies have demonstrated that the rats subjected to SPS show sleep abnormalities, aberrant anxiety, enhanced contextual fear response, and impaired fear extinction [<xref ref-type="bibr" rid="B112-ijms-20-03614">112</xref>,<xref ref-type="bibr" rid="B113-ijms-20-03614">113</xref>,<xref ref-type="bibr" rid="B114-ijms-20-03614">114</xref>,<xref ref-type="bibr" rid="B115-ijms-20-03614">115</xref>]. Moreover, rats subjected to predator-based psychosocial stress (PPS; subjected to unstable housing conditions [changing housing pair] for 31 consecutive days, followed by 1 h of immobilization and exposure to a cat on day 1 and day 11) or predator scent stress (PSS; 10 min of inescapable exposure to well-soiled cat litter) exhibit PTSD-like anxiety behaviors and impaired fear extinction, which have been proposed as the symptoms in animal models of PTSD [<xref ref-type="bibr" rid="B116-ijms-20-03614">116</xref>,<xref ref-type="bibr" rid="B117-ijms-20-03614">117</xref>,<xref ref-type="bibr" rid="B118-ijms-20-03614">118</xref>,<xref ref-type="bibr" rid="B119-ijms-20-03614">119</xref>]. Additionally, many studies have focused on the process of fear extinction following contextual or cued fear conditioning in the rodents as a predominant symptom of PTSD [<xref ref-type="bibr" rid="B105-ijms-20-03614">105</xref>,<xref ref-type="bibr" rid="B120-ijms-20-03614">120</xref>]. Most of the drugs with the reported clinical efficacy have demonstrated anti-PTSD characteristics in the rodent models (<xref ref-type="table" rid="ijms-20-03614-t001">Table 1</xref>) [<xref ref-type="bibr" rid="B95-ijms-20-03614">95</xref>,<xref ref-type="bibr" rid="B96-ijms-20-03614">96</xref>,<xref ref-type="bibr" rid="B97-ijms-20-03614">97</xref>,<xref ref-type="bibr" rid="B98-ijms-20-03614">98</xref>,<xref ref-type="bibr" rid="B99-ijms-20-03614">99</xref>,<xref ref-type="bibr" rid="B100-ijms-20-03614">100</xref>,<xref ref-type="bibr" rid="B101-ijms-20-03614">101</xref>,<xref ref-type="bibr" rid="B102-ijms-20-03614">102</xref>,<xref ref-type="bibr" rid="B103-ijms-20-03614">103</xref>,<xref ref-type="bibr" rid="B104-ijms-20-03614">104</xref>,<xref ref-type="bibr" rid="B106-ijms-20-03614">106</xref>,<xref ref-type="bibr" rid="B107-ijms-20-03614">107</xref>,<xref ref-type="bibr" rid="B108-ijms-20-03614">108</xref>,<xref ref-type="bibr" rid="B109-ijms-20-03614">109</xref>], suggesting that the efficacy of drugs was initially evaluated using the above animal models. However, whether the chronic stress-induced models reflect PTSD pathology is still questionable, due to the lack of reproducibility in different studies. </p>
<p>To resolve these drawbacks, genetically modified animals have been useful in recent times for investigation of the neuronal mechanisms underlying the development and retention of PTSD. Several studies have indicated a relationship between PTSD symptoms and the serotonergic system. Serotonin 1A (5-HT<sub>1A</sub>) receptor knockout (KO) mice exhibit elevated anxiety-like behavior and fear retrieval [<xref ref-type="bibr" rid="B121-ijms-20-03614">121</xref>,<xref ref-type="bibr" rid="B122-ijms-20-03614">122</xref>,<xref ref-type="bibr" rid="B123-ijms-20-03614">123</xref>]. On the other hand, lack of 5-HT<sub>1A</sub> receptor does not affect the process of fear extinction in mice [<xref ref-type="bibr" rid="B123-ijms-20-03614">123</xref>], suggesting that 5-HT<sub>1A</sub> receptor may be associated with fear memory retrieval and consolidation. Additionally, deletion of the gene coding for 5-HT transporter in mice impairs fear extinction recall and enhances PTSD-like behaviors following exposure to predator odor [<xref ref-type="bibr" rid="B124-ijms-20-03614">124</xref>,<xref ref-type="bibr" rid="B125-ijms-20-03614">125</xref>]. Deficiency of pheochromocytoma 12 ETS (E26 transformation-specific) factor (Pet-1) has shown to reduce the mRNA levels of tryptophan hydroxylase 2 (TPH2) and 5-HT<sub>1A</sub> receptor, as well as the immunoreactivities of TPH2 and 5-HT in dorsal raphe [<xref ref-type="bibr" rid="B126-ijms-20-03614">126</xref>]. Following the reduction of the serotonergic system in the mouse brain [<xref ref-type="bibr" rid="B126-ijms-20-03614">126</xref>], Pet-1 KO mice show increased anxiety, aggressive behaviors, and elevated fear response [<xref ref-type="bibr" rid="B127-ijms-20-03614">127</xref>,<xref ref-type="bibr" rid="B128-ijms-20-03614">128</xref>]. Pet-1 KO mice also display delayed fear extinction learning, but it does not affect the process [<xref ref-type="bibr" rid="B128-ijms-20-03614">128</xref>]. Moreover, fMRI analyses have revealed that the threat-induced amygdala hyperactivation is associated with human Pet-1 variant [<xref ref-type="bibr" rid="B128-ijms-20-03614">128</xref>]. Thus, hypofunction of serotonergic systems may reflect one of the aspects of the PTSD symptoms. Additionally, other genetic models have been proposed. The brain-derived neurotrophic factor, Met allele, has been associated with PTSD and impairment of fear extinction learning in mice [<xref ref-type="bibr" rid="B129-ijms-20-03614">129</xref>,<xref ref-type="bibr" rid="B130-ijms-20-03614">130</xref>]. Conditional KO of the corticotrophin-releasing hormone receptor type-1 gene in the limbic forebrain of mouse decreases remote associative and non-associative fear memory [<xref ref-type="bibr" rid="B131-ijms-20-03614">131</xref>]. Mice with neuropeptide Y gene KO show potentiated acquisition of conditioned fear memory and impaired fear extinction [<xref ref-type="bibr" rid="B132-ijms-20-03614">132</xref>]. Moreover, mice with overexpressed adult cholecystokinin receptor-2 display PTSD-like behavioral deficits when subjected to traumatic stimuli (foot-shocks) during puberty [<xref ref-type="bibr" rid="B133-ijms-20-03614">133</xref>], suggesting that the interaction of genetic factor with the early environmental condition have an impact on the post-pubertal behavioral phenotype. These observations suggest that various genes are involved in altering the associated neuronal networks in PTSD; however, the molecular mechanism of fear extinction processing remains unclear. </p>
</sec>
<sec id="sec5-ijms-20-03614">
<title>5. Role of Long-Chain Polyunsaturated Fatty Acids (LCPUFAs) and Fatty Acid Binding Proteins (FABPs) in the Brain</title>
<p>In the brain, LCPUFAs are an essential component of membrane phospholipids and important for brain development [<xref ref-type="bibr" rid="B134-ijms-20-03614">134</xref>,<xref ref-type="bibr" rid="B135-ijms-20-03614">135</xref>]. Aberrant metabolism of LCPUFAs has been reported in various psychiatric diseases. For example, levels of ω3 and ω6 LCPUFAs in the membrane of red blood cells are decreased in the schizophrenia subjects, while ω3 LCPUFA levels are reduced in the plasma of the autistic subjects [<xref ref-type="bibr" rid="B136-ijms-20-03614">136</xref>,<xref ref-type="bibr" rid="B137-ijms-20-03614">137</xref>,<xref ref-type="bibr" rid="B138-ijms-20-03614">138</xref>]. Likewise, the concentration of ω3 LCPUFA is significantly decreased in the erythrocytes and plasma of PTSD patients [<xref ref-type="bibr" rid="B139-ijms-20-03614">139</xref>]. Consistent with the observation, ω3 LCPUFA supplementation has shown to prevent the development of PTSD and also reduce the PTSD symptoms after accidental injuries, including the Great East Japan Earthquake [<xref ref-type="bibr" rid="B140-ijms-20-03614">140</xref>,<xref ref-type="bibr" rid="B141-ijms-20-03614">141</xref>,<xref ref-type="bibr" rid="B142-ijms-20-03614">142</xref>]. Studies have also demonstrated that the effect of ω3 LCPUFAs on the PTSD symptoms could be due to the elevation in the hippocampal neurogenesis [<xref ref-type="bibr" rid="B140-ijms-20-03614">140</xref>,<xref ref-type="bibr" rid="B141-ijms-20-03614">141</xref>], since the hippocampus-dependent fear memory is closely associated with the activity of neurogenesis in mouse hippocampal dentate gyrus (DG) [<xref ref-type="bibr" rid="B143-ijms-20-03614">143</xref>]. Indeed, ω3 LCPUFA administration has shown to facilitate mouse and rat hippocampal neurogenesis [<xref ref-type="bibr" rid="B144-ijms-20-03614">144</xref>,<xref ref-type="bibr" rid="B145-ijms-20-03614">145</xref>]. Taken together, disturbances in the LCPUFA supplementation and metabolism may be associated with the PTSD symptoms.</p>
<p>FABPs, low molecular weight (14–15 kDa) proteins with twelve subtypes in most mammals, have a key role in the intracellular uptake, transport, and metabolism of LCPUFAs [<xref ref-type="bibr" rid="B146-ijms-20-03614">146</xref>,<xref ref-type="bibr" rid="B147-ijms-20-03614">147</xref>]. In the mouse and human brain, three types of FABPs, FABP3, FABP5, and FABP7 are primarily expressed [<xref ref-type="bibr" rid="B148-ijms-20-03614">148</xref>]. While FABP5 and FABP7 are localized in the glial and neuronal stem/progenitor cells, FABP3 is expressed in the mature neuronal cells [<xref ref-type="bibr" rid="B148-ijms-20-03614">148</xref>,<xref ref-type="bibr" rid="B149-ijms-20-03614">149</xref>]. Lack of <italic>Fabp5</italic> and/or <italic>Fabp7</italic> reduces the proliferation of neural stem cells in the mouse hippocampal DG [<xref ref-type="bibr" rid="B149-ijms-20-03614">149</xref>], and <italic>Fabp7</italic> null mice exhibit impaired emotional behaviors, including aberrant fear response, sensory motor dysfunction, and sleep disturbance [<xref ref-type="bibr" rid="B150-ijms-20-03614">150</xref>,<xref ref-type="bibr" rid="B151-ijms-20-03614">151</xref>]. We previously have demonstrated that FABP3 interacts with the dopamine D2 receptor long isoform (D2LR), and that deficiency of <italic>Fabp3</italic> reduces methamphetamine-induced sensitization and increases haloperidol-induced catalepsy, due to the dysfunction of dopamine D2 receptors [<xref ref-type="bibr" rid="B152-ijms-20-03614">152</xref>,<xref ref-type="bibr" rid="B153-ijms-20-03614">153</xref>]. Indeed, <italic>Fabp3</italic> null mice are resistant to dopaminergic toxicity-induced parkinsonism [<xref ref-type="bibr" rid="B154-ijms-20-03614">154</xref>]. Moreover, <italic>Fabp3</italic>, <italic>Fabp5,</italic> and <italic>Fabp7</italic> gene variants have been identified in patients with schizophrenia and autism spectrum disorder [<xref ref-type="bibr" rid="B155-ijms-20-03614">155</xref>]. These observations suggest that dysfunction of FABPs in the brain is associated with the development of a psychiatric disorder.</p>
</sec>
<sec id="sec6-ijms-20-03614">
<title>6. Impaired Fear Extinction Process in <italic>Fabp3</italic> Null Mice</title>
<p>To assess the fear process of extinction acquisition and extinction, a mouse is placed in a box with dark and light compartments, shown in <xref ref-type="fig" rid="ijms-20-03614-f001">Figure 1</xref>, and the step-through latency is recorded up to 300 sec with or without electric shock (Day 1–4; <xref ref-type="fig" rid="ijms-20-03614-f001">Figure 1</xref>). No differences were observed during fear acquisition (Day 1–4) and retrieval (Day 5) between wild-type (WT) and <italic>Fabp3</italic> null mice (<xref ref-type="fig" rid="ijms-20-03614-f002">Figure 2</xref>). WT mice showed normal fear extinction process from Day 12 to Day 35 gradually; however, <italic>Fabp3</italic> null mice failed, suggesting that <italic>Fabp3</italic> deficiency impairs fear extinction processing (<xref ref-type="fig" rid="ijms-20-03614-f002">Figure 2</xref>) [<xref ref-type="bibr" rid="B156-ijms-20-03614">156</xref>]. <italic>Fabp3</italic> null mice also exhibited cognitive impairment, increased daytime locomotor activity, which may reflect sleep disturbance, and anxiety behaviors [<xref ref-type="bibr" rid="B156-ijms-20-03614">156</xref>,<xref ref-type="bibr" rid="B157-ijms-20-03614">157</xref>], suggesting that <italic>Fabp3</italic> null mice may display PTSD-like behaviors. Consistent with clinical investigations, the level of c-Fos, as an indicator of neuronal activity, was markedly elevated in the BLA of <italic>Fabp3</italic> null mice one hour after the exposure of fear on Day 35 (<xref ref-type="fig" rid="ijms-20-03614-f003">Figure 3</xref>a,b) [<xref ref-type="bibr" rid="B156-ijms-20-03614">156</xref>]. <italic>N</italic>-methyl-<italic>d</italic>-aspartate (NMDA) receptor signaling plays an essential role in fear response and c-Fos expression [<xref ref-type="bibr" rid="B158-ijms-20-03614">158</xref>,<xref ref-type="bibr" rid="B159-ijms-20-03614">159</xref>,<xref ref-type="bibr" rid="B160-ijms-20-03614">160</xref>], and one of its major downstream targets calcium/calmodulin-dependent protein kinase II (CaMKII) phosphorylation levels are significantly reduced in the ACC and conversely elevated in the BLA of <italic>Fabp3</italic> null mice as compared to WT mice [<xref ref-type="bibr" rid="B156-ijms-20-03614">156</xref>], indicating hypofunction and hyperactivation in the <italic>Fabp3</italic> null ACC and BLA, respectively. FABP3 is highly localized in the parvalbumin-positive GABAnergic neurons in mouse ACC, and the GABAnergic neuronal activities are elevated in the ACC of <italic>Fabp3</italic> null mice, thereby attenuating glutamatergic neurotransmission [<xref ref-type="bibr" rid="B157-ijms-20-03614">157</xref>]. Since the neuronal activity of ACC negatively regulates BLA neuronal activity and thus, suppresses overactivation of BLA neuronal circuit [<xref ref-type="bibr" rid="B43-ijms-20-03614">43</xref>,<xref ref-type="bibr" rid="B44-ijms-20-03614">44</xref>,<xref ref-type="bibr" rid="B45-ijms-20-03614">45</xref>]. We, therefore, speculate that the hypofunction in ACC fails to suppress aberrant BLA neuronal activation during fear conditioning, thereby, impairing the process of fear extinction in <italic>Fabp3</italic> null mice. These changes in the brain activities of <italic>Fabp3</italic> null mice are likely to be similar to that observed in subjects with PTSD [<xref ref-type="bibr" rid="B33-ijms-20-03614">33</xref>,<xref ref-type="bibr" rid="B34-ijms-20-03614">34</xref>,<xref ref-type="bibr" rid="B35-ijms-20-03614">35</xref>,<xref ref-type="bibr" rid="B36-ijms-20-03614">36</xref>,<xref ref-type="bibr" rid="B37-ijms-20-03614">37</xref>,<xref ref-type="bibr" rid="B38-ijms-20-03614">38</xref>,<xref ref-type="bibr" rid="B39-ijms-20-03614">39</xref>,<xref ref-type="bibr" rid="B46-ijms-20-03614">46</xref>,<xref ref-type="bibr" rid="B47-ijms-20-03614">47</xref>], and moreover, this is first report to demonstrate the relationship between FABP and PTSD, suggesting that <italic>Fabp3</italic> null mice are useful genetic models to study the pathophysiology, and assess the effect of novel candidate drugs on PTSD symptom.</p>
</sec>
<sec id="sec7-ijms-20-03614">
<title>7. Potential Efficacy of Melatonin Receptor Agonist for PTSD Symptom</title>
<p>Melatonin, a pineal hormone synthesized from serotonin, mediates circadian rhythms, sleep, mood, and cognition [<xref ref-type="bibr" rid="B161-ijms-20-03614">161</xref>,<xref ref-type="bibr" rid="B162-ijms-20-03614">162</xref>], and Huang et al. in their study observed that melatonin treatment facilitates fear extinction in naïve rats [<xref ref-type="bibr" rid="B163-ijms-20-03614">163</xref>]. The melatonin receptor selective agonist, ramelteon, shows a 3- to 7-fold higher affinity and 5.5- to 9.6-fold greater potency for recombinant monkey and human MT1/MT2 receptors than that of melatonin and has been approved for insomnia in clinical therapy [<xref ref-type="bibr" rid="B164-ijms-20-03614">164</xref>]. Therefore, we evaluated the effect of ramelteon on impaired fear extinction in <italic>Fabp3</italic> null mice. Administration of ramelteon (1.0 mg/kg, p.o.) significantly relieved not only PTSD-like symptom, including impaired fear extinction, but also pathological changes in <italic>Fabp3</italic> null mice (<xref ref-type="fig" rid="ijms-20-03614-f002">Figure 2</xref>, <xref ref-type="fig" rid="ijms-20-03614-f003">Figure 3</xref>a). Melatonin receptor antagonist, luzindole (2.5 mg/kg, i.p.) treatment prevents the effect of ramelteon in <italic>Fabp3</italic> null mice (<xref ref-type="fig" rid="ijms-20-03614-f002">Figure 2</xref>, <xref ref-type="fig" rid="ijms-20-03614-f003">Figure 3</xref>a), suggesting that improvement by ramelteon may be due to activating the melatonin receptors. Importantly, melatonin MT1 and MT2 receptors are highly expressed in rodent PFC, including ACC, and are almost absent in the amygdala [<xref ref-type="bibr" rid="B165-ijms-20-03614">165</xref>]. Since treatment with melatonin enhances the reduced CaMKII autophosphorylation levels in the hippocampal CA1 region and then improves the cognitive impairment in an animal model of autism [<xref ref-type="bibr" rid="B166-ijms-20-03614">166</xref>], we suggest that ramelteon initially improves the decreased CaMKII activity (neuronal activity) in the ACC and in turn suppresses the elevated neuronal and CaMKII activities in the BLA, thereby, reversing the impaired fear extinction in <italic>Fabp3</italic> null mice (<xref ref-type="fig" rid="ijms-20-03614-f004">Figure 4</xref>). </p>
<p>The previous report indicates that stimulation of Gi-coupled receptor triggers the Gβγ-phospholipase Cβ (PLCβ) pathway and then elevates intracellular calcium levels by activating the inositol 1,4,5-trisphosphate receptors [<xref ref-type="bibr" rid="B167-ijms-20-03614">167</xref>], suggesting one of the mechanisms underlying CaMKII activation by stimulation of melatonin receptors. In an ex vivo experiment, melatonin incubation in the brain slices enhanced the dendrite length, thickness, and complexity in the rat hippocampal neurons via CaMKII activation [<xref ref-type="bibr" rid="B168-ijms-20-03614">168</xref>]. Glutamate (10 μM) application failed to activate calcium signaling, including CaMKII in mouse cortical primary neurons on DIV 21, due to spontaneous firing; however, it significantly enhanced CaMKII autophosphorylation levels under melatonin (5 μM) treatment [<xref ref-type="bibr" rid="B169-ijms-20-03614">169</xref>]. Since levels of melatonin in the rat brain fluctuate with the circadian rhythm [<xref ref-type="bibr" rid="B170-ijms-20-03614">170</xref>], CaMKII activation by glutamate application with melatonin treatment may reset the circadian rhythm in the suprachiasmatic nucleus in mice [<xref ref-type="bibr" rid="B170-ijms-20-03614">170</xref>]. Additionally, NMDA receptor partial agonist, D-cycloserine, has demonstrated to facilitate fear extinction in animal models and patients with PTSD [<xref ref-type="bibr" rid="B171-ijms-20-03614">171</xref>,<xref ref-type="bibr" rid="B172-ijms-20-03614">172</xref>,<xref ref-type="bibr" rid="B173-ijms-20-03614">173</xref>]. Taken together, hypofunction in ACC may fail to attenuate neuronal hyperactivity in BLA after contextual fear retrieval and in turn may impair fear extinction in <italic>Fabp3</italic> null mice. Furthermore, ramelteon can antagonize the PTSD-like behaviors by MT receptor stimulation, and, hence, suppress the hyperactivation of BLA in <italic>Fabp3</italic> null mice (<xref ref-type="fig" rid="ijms-20-03614-f004">Figure 4</xref>). Although the mechanism of action of ramelteon on CaMKII activation through the stimulation of Gi protein-coupled melatonin receptors is not clear, recent work on the protective functions of melatonin, especially in cognitive impairment implies the involvement of other kinases [<xref ref-type="bibr" rid="B174-ijms-20-03614">174</xref>].</p>
<p>Although the clinical trial of patients experiencing PTSD with melatonin or ramelteon has not been conducted yet, reduced melatonin levels in the first 48 h after exposure to traumatic stress may be associated with a higher risk for PTSD [<xref ref-type="bibr" rid="B175-ijms-20-03614">175</xref>]. Since the melatonin system plays an important role in sleep, cognitive function, pain, neuroimmunomodulation, stress response (HPA axis), circadian rhythm, and oxidative stress, all of which are affected in case of PTSD, upregulation of the melatonergic system could provide a potentially promising treatment strategy in the management of PTSD symptoms [<xref ref-type="bibr" rid="B176-ijms-20-03614">176</xref>,<xref ref-type="bibr" rid="B177-ijms-20-03614">177</xref>]. Here, we demonstrate the effect of ramelteon on PTSD-like behaviors in <italic>Fabp3</italic> null mice. As ramelteon has been approved for treating sleep disturbance, the schedule of administration will be considered. In conclusion, we propose and hope that ramelteon is repurposed as a novel therapeutic for treating PTSD in the near future.</p>
</sec>
<sec id="sec8-ijms-20-03614" sec-type="conclusions">
<title>8. Conclusions</title>
<p>In the present article, we have reviewed the predicted neuronal circuits and evidenced therapeutics in PTSD symptoms according to clinical and basic animal studies. Additionally, we introduce and discuss <italic>Fabp3</italic> null mice as a useful animal model of PTSD to investigate the neurochemical basis of fear extinction processing. Similar to clinical observations, impaired neuronal activities in the ACC and BLA were found to be associated with PTSD-like behaviors in <italic>Fabp3</italic> null mice, suggesting the potential role of FABP3 in PTSD. In another study, decreased levels of stress-related intracellular molecules, such as serum/glucocorticoid regulated kinase 1 and FK506 binding protein 5 were observed in the PFC of PTSD subject’s postmortem, and also have been associated with fear response in rodents [<xref ref-type="bibr" rid="B44-ijms-20-03614">44</xref>]. Melatonin receptor activation reduces cyclin-dependent kinase 5 (Cdk5) expression [<xref ref-type="bibr" rid="B178-ijms-20-03614">178</xref>], and this increase in Cdk5 expression attenuates fear memory retrieval [<xref ref-type="bibr" rid="B179-ijms-20-03614">179</xref>]; therefore, the relationship between the dopamine D2 receptors and PTSD-like behaviors in <italic>Fabp3</italic> null mice can be explored. Further studies are necessary to establish the mechanisms underlying the impaired fear extinction in <italic>Fabp3</italic> null mice. On the other hand, melatonin receptor agonist, ramelteon, antagonized the PTSD-like behaviors in <italic>Fabp3</italic> null mice, and therefore, we suggest that melatonin receptors may be a novel therapeutic target and ramelteon can be an effective drug candidate for the PTSD symptoms. As ramelteon has been approved for insomnia, preclinical studies and clinical trials will be helpful in the establishment of ramelteon as a PTSD therapy in the near future.</p>
</sec>
</body>
<back>
<notes>
<title>Funding</title>
<p>This work was supported in part by grants-in-aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan (Kakenhi: 26102704 to K.F.), Takeda Science Foundation (to Y.Y.), and the Strategic Research Program for Brain Sciences from Japan Agency for Medical Research and Development, AMED (to K.F.).</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflict of interest.</p>
</notes>
<glossary>
<title>Abbreviations</title>
<array orientation="portrait">
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">ACC</td>
<td align="left" colspan="1" rowspan="1" valign="top">anterior cingulated cortex</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">BLA</td>
<td align="left" colspan="1" rowspan="1" valign="top">basolateral amygdala</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CaMKII</td>
<td align="left" colspan="1" rowspan="1" valign="top">calcium/calmodulin-dependent protein kinase II</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CBT</td>
<td align="left" colspan="1" rowspan="1" valign="top">cognitive behavioral therapy</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cdk5</td>
<td align="left" colspan="1" rowspan="1" valign="top">cyclin-dependent kinase 5</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">DG</td>
<td align="left" colspan="1" rowspan="1" valign="top">dentate gyrus</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">EMDR</td>
<td align="left" colspan="1" rowspan="1" valign="top">eye movement desensitization and reprocessing</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">FABP</td>
<td align="left" colspan="1" rowspan="1" valign="top">fatty acid binding protein</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">fMRI</td>
<td align="left" colspan="1" rowspan="1" valign="top">functional magnetic resonance imaging</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">GABA</td>
<td align="left" colspan="1" rowspan="1" valign="top">γ-aminobutyric acid</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">HPA</td>
<td align="left" colspan="1" rowspan="1" valign="top">hypothalamo-pituitary-adrenal</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">5-HT</td>
<td align="left" colspan="1" rowspan="1" valign="top">serotonin</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">IRT</td>
<td align="left" colspan="1" rowspan="1" valign="top">imagery rehearsal therapy</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">LCPUFA</td>
<td align="left" colspan="1" rowspan="1" valign="top">long-chain polyunsaturated fatty acid</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">MRI</td>
<td align="left" colspan="1" rowspan="1" valign="top">magnetic resonance imaging</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">NMDA</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>N</italic>-methyl-<italic>d</italic>-aspartate</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">PFC</td>
<td align="left" colspan="1" rowspan="1" valign="top">prefrontal cortex</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">PTSD</td>
<td align="left" colspan="1" rowspan="1" valign="top">Post-traumatic stress disorder</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">QOL</td>
<td align="left" colspan="1" rowspan="1" valign="top">quality of life</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">SNRI</td>
<td align="left" colspan="1" rowspan="1" valign="top">serotonin and noradrenaline reuptake inhibitor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">SPS</td>
<td align="left" colspan="1" rowspan="1" valign="top">Single prolonged stress</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">SSRI</td>
<td align="left" colspan="1" rowspan="1" valign="top">selective serotonin reuptake inhibitor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">WT</td>
<td align="left" colspan="1" rowspan="1" valign="top">wild-type</td>
</tr>
</tbody>
</array>
</glossary>
<ref-list>
<title>References</title>
<ref id="B1-ijms-20-03614">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Foa</surname>
<given-names>E.B.</given-names>
</name>
<name>
<surname>Gillihan</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Bryant</surname>
<given-names>R.A.</given-names>
</name>
</person-group>
<article-title>Challenges and Successes in Dissemination of Evidence-Based Treatments for Posttraumatic Stress: Lessons Learned From Prolonged Exposure Therapy for PTSD</article-title>
<source/>Psychol. Sci. Public Interest
          <year>2013</year>
<volume>14</volume>
<fpage>65</fpage>
<lpage>111</lpage>
<pub-id pub-id-type="doi">10.1177/1529100612468841</pub-id>
<pub-id pub-id-type="pmid">25722657</pub-id>
</element-citation>
</ref>
<ref id="B2-ijms-20-03614">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Javidi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yadollahie</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Post-traumatic Stress Disorder</article-title>
<source/>Int. J. Occup. Environ Med.
          <year>2012</year>
<volume>3</volume>
<fpage>2</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">23022845</pub-id>
</element-citation>
</ref>
<ref id="B3-ijms-20-03614">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kessler</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Chiu</surname>
<given-names>W.T.</given-names>
</name>
<name>
<surname>Demler</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Merikangas</surname>
<given-names>K.R.</given-names>
</name>
<name>
<surname>Walters</surname>
<given-names>E.E.</given-names>
</name>
</person-group>
<article-title>Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication</article-title>
<source/>Arch. Gen. Psychiatry
          <year>2005</year>
<volume>62</volume>
<fpage>617</fpage>
<lpage>627</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.62.6.617</pub-id>
<pub-id pub-id-type="pmid">15939839</pub-id>
</element-citation>
</ref>
<ref id="B4-ijms-20-03614">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldstein</surname>
<given-names>R.B.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Chou</surname>
<given-names>S.P.</given-names>
</name>
<name>
<surname>Saha</surname>
<given-names>T.D.</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Pickering</surname>
<given-names>R.P.</given-names>
</name>
<name>
<surname>Ruan</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>B.F.</given-names>
</name>
</person-group>
<article-title>The epidemiology of DSM-5 posttraumatic stress disorder in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions-III</article-title>
<source/>Soc. Psychiatry Psychiatr. Epidemiol.
          <year>2016</year>
<volume>51</volume>
<fpage>1137</fpage>
<lpage>1148</lpage>
<pub-id pub-id-type="doi">10.1007/s00127-016-1208-5</pub-id>
<pub-id pub-id-type="pmid">27106853</pub-id>
</element-citation>
</ref>
<ref id="B5-ijms-20-03614">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawakami</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tsuchiya</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Umeda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Koenen</surname>
<given-names>K.C.</given-names>
</name>
<name>
<surname>Kessler</surname>
<given-names>R.C.</given-names>
</name>
</person-group>
<article-title>World Mental Health Survey Japan. Trauma and posttraumatic stress disorder in Japan: Results from the World Mental Health Japan Survey</article-title>
<source/>J. Psychiatr. Res.
          <year>2014</year>
<volume>53</volume>
<fpage>157</fpage>
<lpage>165</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2014.01.015</pub-id>
<pub-id pub-id-type="pmid">24572682</pub-id>
</element-citation>
</ref>
<ref id="B6-ijms-20-03614">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fullerton</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Ursano</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Acute stress disorder, posttraumatic stress disorder, and depression in disaster or rescue workers</article-title>
<source/>Am. J. Psychiatry
          <year>2004</year>
<volume>161</volume>
<fpage>1370</fpage>
<lpage>1376</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.161.8.1370</pub-id>
<pub-id pub-id-type="pmid">15285961</pub-id>
</element-citation>
</ref>
<ref id="B7-ijms-20-03614">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsubara</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Murakami</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Imai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mizoue</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Akashi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Miyoshi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nakasa</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Prevalence and Risk Factors for Post-Traumatic Stress Reaction Among Resident Survivors of the Tsunami That Followed the Great East Japan Earthquake, March 11, 2011</article-title>
<source/>Disaster Med. Public Health Prep.
          <year>2016</year>
<volume>10</volume>
<fpage>746</fpage>
<lpage>753</lpage>
<pub-id pub-id-type="doi">10.1017/dmp.2016.18</pub-id>
<pub-id pub-id-type="pmid">27075401</pub-id>
</element-citation>
</ref>
<ref id="B8-ijms-20-03614">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schlenger</surname>
<given-names>W.E.</given-names>
</name>
<name>
<surname>Caddell</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Ebert</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jordan</surname>
<given-names>B.K.</given-names>
</name>
<name>
<surname>Rourke</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Thalji</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dennis</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Fairbank</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Kulka</surname>
<given-names>R.A.</given-names>
</name>
</person-group>
<article-title>Psychological reactions to terrorist attacks: Findings from the National Study of Americans’ Reactions to September 11</article-title>
<source/>JAMA
          <year>2002</year>
<volume>288</volume>
<fpage>581</fpage>
<lpage>588</lpage>
<pub-id pub-id-type="doi">10.1001/jama.288.5.581</pub-id>
<pub-id pub-id-type="pmid">12150669</pub-id>
</element-citation>
</ref>
<ref id="B9-ijms-20-03614">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turner</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rosser</surname>
<given-names>R.M.</given-names>
</name>
</person-group>
<article-title>The Kings Cross fire: Psychological reactions</article-title>
<source/>J. Trauma Stress
          <year>1995</year>
<volume>8</volume>
<fpage>419</fpage>
<lpage>427</lpage>
<pub-id pub-id-type="doi">10.1002/jts.2490080305</pub-id>
<pub-id pub-id-type="pmid">7582607</pub-id>
</element-citation>
</ref>
<ref id="B10-ijms-20-03614">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Havenaar</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Rumyantzeva</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>van den Brink</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Poelijoe</surname>
<given-names>N.W.</given-names>
</name>
<name>
<surname>van den Bout</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>van Engeland</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Koeter</surname>
<given-names>M.W.</given-names>
</name>
</person-group>
<article-title>Long-term mental health effects of the Chernobyl disaster: An epidemiologic survey in two former Soviet regions</article-title>
<source/>Am. J. Psychiatry
          <year>1997</year>
<volume>154</volume>
<fpage>1605</fpage>
<lpage>1607</lpage>
<pub-id pub-id-type="doi">10.1176/ajp.154.11.1605</pub-id>
<pub-id pub-id-type="pmid">9356574</pub-id>
</element-citation>
</ref>
<ref id="B11-ijms-20-03614">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ressler</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Mayberg</surname>
<given-names>H.S.</given-names>
</name>
</person-group>
<article-title>Targeting abnormal neural circuits in mood and anxiety disorders: From the laboratory to the clinic</article-title>
<source/>Nat. Neurosci.
          <year>2007</year>
<volume>10</volume>
<fpage>1116</fpage>
<lpage>1124</lpage>
<pub-id pub-id-type="doi">10.1038/nn1944</pub-id>
<pub-id pub-id-type="pmid">17726478</pub-id>
</element-citation>
</ref>
<ref id="B12-ijms-20-03614">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Waltman</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Shearer</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>B.A.</given-names>
</name>
</person-group>
<article-title>Management of Post-Traumatic Nightmares: A Review of Pharmacologic and Nonpharmacologic Treatments Since 2013</article-title>
<source/>Curr. Psychiatry Rep.
          <year>2018</year>
<volume>20</volume>
<fpage>108</fpage>
<pub-id pub-id-type="doi">10.1007/s11920-018-0971-2</pub-id>
<pub-id pub-id-type="pmid">30306339</pub-id>
</element-citation>
</ref>
<ref id="B13-ijms-20-03614">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bremner</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Delaney</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Southwick</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Mason</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Innis</surname>
<given-names>R.B.</given-names>
</name>
<name>
<surname>McCarthy</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Charney</surname>
<given-names>D.S.</given-names>
</name>
</person-group>
<article-title>Deficits in short-term memory in posttraumatic stress disorder</article-title>
<source/>Am. J. Psychiatry
          <year>1993</year>
<volume>150</volume>
<fpage>1015</fpage>
<lpage>1019</lpage>
<pub-id pub-id-type="doi">10.1176/ajp.150.7.1015</pub-id>
<pub-id pub-id-type="pmid">8317569</pub-id>
</element-citation>
</ref>
<ref id="B14-ijms-20-03614">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vasterling</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Duke</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Brailey</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Constans</surname>
<given-names>J.I.</given-names>
</name>
<name>
<surname>Allain</surname>
<given-names>A.N.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Sutker</surname>
<given-names>P.B.</given-names>
</name>
</person-group>
<article-title>Attention, learning, and memory performances and intellectual resources in Vietnam veterans: PTSD and no disorder comparisons</article-title>
<source/>Neuropsychology
          <year>2002</year>
<volume>16</volume>
<fpage>5</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="doi">10.1037/0894-4105.16.1.5</pub-id>
<pub-id pub-id-type="pmid">11853357</pub-id>
</element-citation>
</ref>
<ref id="B15-ijms-20-03614">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moser</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Aue</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Suardi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kutlikova</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Cordero</surname>
<given-names>M.I.</given-names>
</name>
<name>
<surname>Rossignol</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Favez</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Rusconi Serpa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Schechter</surname>
<given-names>D.S.</given-names>
</name>
</person-group>
<article-title>Violence-related PTSD and neural activation when seeing emotionally charged male-female interactions</article-title>
<source/>Soc. Cogn. Affect. Neurosci.
          <year>2015</year>
<volume>10</volume>
<fpage>645</fpage>
<lpage>653</lpage>
<pub-id pub-id-type="doi">10.1093/scan/nsu099</pub-id>
<pub-id pub-id-type="pmid">25062841</pub-id>
</element-citation>
</ref>
<ref id="B16-ijms-20-03614">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.Q.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>X.Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Sheng</surname>
<given-names>Z.F.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.L.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.P.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Z.G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Different neural circuitry is involved in physiological and psychological stress-induced PTSD-like “nightmares” in rats</article-title>
<source/>Sci. Rep.
          <year>2015</year>
<volume>5</volume>
<fpage>15976</fpage>
<pub-id pub-id-type="doi">10.1038/srep15976</pub-id>
<pub-id pub-id-type="pmid">26530305</pub-id>
</element-citation>
</ref>
<ref id="B17-ijms-20-03614">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paintain</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Cassidy</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>First-line therapy for post-traumatic stress disorder: A systematic review of cognitive behavioural therapy and psychodynamic approaches</article-title>
<source/>Couns. Psychother. Res.
          <year>2018</year>
<volume>18</volume>
<fpage>237</fpage>
<lpage>250</lpage>
<pub-id pub-id-type="doi">10.1002/capr.12174</pub-id>
<pub-id pub-id-type="pmid">30147450</pub-id>
</element-citation>
</ref>
<ref id="B18-ijms-20-03614">
<label>18.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Forman-Hoffman</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Middleton</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Feltner</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gaynes</surname>
<given-names>B.N.</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>R.P.</given-names>
</name>
<name>
<surname>Bann</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Viswanathan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lohr</surname>
<given-names>K.N.</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>J.</given-names>
</name>
</person-group>
<source/>Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update
          <comment>Report No.: 18-EHC011-EF</comment>
<publisher-name>Agency for Healthcare Research and Quality (US)</publisher-name>
<publisher-loc>Rockville, MD, USA</publisher-loc>
<year>2018</year>
</element-citation>
</ref>
<ref id="B19-ijms-20-03614">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Milad</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Quirk</surname>
<given-names>G.J.</given-names>
</name>
</person-group>
<article-title>Neurons in medial prefrontal cortex signal memory for fear extinction</article-title>
<source/>Nature
          <year>2002</year>
<volume>420</volume>
<fpage>70</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1038/nature01138</pub-id>
<pub-id pub-id-type="pmid">12422216</pub-id>
</element-citation>
</ref>
<ref id="B20-ijms-20-03614">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parsons</surname>
<given-names>R.G.</given-names>
</name>
<name>
<surname>Ressler</surname>
<given-names>K.J.</given-names>
</name>
</person-group>
<article-title>Implications of memory modulation for post-traumatic stress and fear disorders</article-title>
<source/>Nat. Neurosci.
          <year>2013</year>
<volume>16</volume>
<fpage>146</fpage>
<lpage>153</lpage>
<pub-id pub-id-type="doi">10.1038/nn.3296</pub-id>
<pub-id pub-id-type="pmid">23354388</pub-id>
</element-citation>
</ref>
<ref id="B21-ijms-20-03614">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilensky</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Schafe</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>Kristensen</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>LeDoux</surname>
<given-names>J.E.</given-names>
</name>
</person-group>
<article-title>Rethinking the fear circuit: The central nucleus of the amygdala is required for the acquisition, consolidation, and expression of Pavlovian fear conditioning</article-title>
<source/>J. Neurosci.
          <year>2006</year>
<volume>26</volume>
<fpage>12387</fpage>
<lpage>12396</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.4316-06.2006</pub-id>
<pub-id pub-id-type="pmid">17135400</pub-id>
</element-citation>
</ref>
<ref id="B22-ijms-20-03614">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quirk</surname>
<given-names>G.J.</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>G.K.</given-names>
</name>
<name>
<surname>Barron</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Lebron</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>The role of ventromedial prefrontal cortex in the recovery of extinguished fear</article-title>
<source/>J. Neurosci.
          <year>2000</year>
<volume>20</volume>
<fpage>6225</fpage>
<lpage>6231</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.20-16-06225.2000</pub-id>
<pub-id pub-id-type="pmid">10934272</pub-id>
</element-citation>
</ref>
<ref id="B23-ijms-20-03614">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Fanselow</surname>
<given-names>M.S.</given-names>
</name>
</person-group>
<article-title>Modality-specific retrograde amnesia of fear</article-title>
<source/>Science
          <year>1992</year>
<volume>256</volume>
<fpage>675</fpage>
<lpage>677</lpage>
<pub-id pub-id-type="doi">10.1126/science.1585183</pub-id>
<pub-id pub-id-type="pmid">1585183</pub-id>
</element-citation>
</ref>
<ref id="B24-ijms-20-03614">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanders</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Fanselow</surname>
<given-names>M.S.</given-names>
</name>
</person-group>
<article-title>Pre-training prevents context fear conditioning deficits produced by hippocampal NMDA receptor blockade</article-title>
<source/>Neurobiol. Learn Mem.
          <year>2003</year>
<volume>80</volume>
<fpage>123</fpage>
<lpage>129</lpage>
<pub-id pub-id-type="doi">10.1016/S1074-7427(03)00040-6</pub-id>
<pub-id pub-id-type="pmid">12932427</pub-id>
</element-citation>
</ref>
<ref id="B25-ijms-20-03614">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sotres-Bayon</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sierra-Mercado</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pardilla-Delgado</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Quirk</surname>
<given-names>G.J.</given-names>
</name>
</person-group>
<article-title>Gating of Fear in Prelimbic Cortex by Hippocampal and Amygdala Inputs</article-title>
<source/>Neuron
          <year>2012</year>
<volume>76</volume>
<fpage>804</fpage>
<lpage>812</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2012.09.028</pub-id>
<pub-id pub-id-type="pmid">23177964</pub-id>
</element-citation>
</ref>
<ref id="B26-ijms-20-03614">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tovote</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Fadok</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Lüthi</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Neuronal circuits for fear and anxiety</article-title>
<source/>Nat. Rev. Neurosci.
          <year>2015</year>
<volume>16</volume>
<fpage>317</fpage>
<lpage>331</lpage>
<pub-id pub-id-type="doi">10.1038/nrn3945</pub-id>
<pub-id pub-id-type="pmid">25991441</pub-id>
</element-citation>
</ref>
<ref id="B27-ijms-20-03614">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klavir</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Prigge</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sarel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Paz</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yizhar</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Manipulating fear associations via optogenetic modulation of amygdala inputs to prefrontal cortex</article-title>
<source/>Nat. Neurosci.
          <year>2017</year>
<volume>20</volume>
<fpage>836</fpage>
<lpage>844</lpage>
<pub-id pub-id-type="doi">10.1038/nn.4523</pub-id>
<pub-id pub-id-type="pmid">28288126</pub-id>
</element-citation>
</ref>
<ref id="B28-ijms-20-03614">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kitayama</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Vaccarino</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Kutner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bremner</surname>
<given-names>J.D.</given-names>
</name>
</person-group>
<article-title>Magnetic resonance imaging (MRI) measurement of hippocampal volume in posttraumatic stress disorder: A meta-analysis</article-title>
<source/>J. Affect. Disord.
          <year>2005</year>
<volume>88</volume>
<fpage>79</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2005.05.014</pub-id>
<pub-id pub-id-type="pmid">16033700</pub-id>
</element-citation>
</ref>
<ref id="B29-ijms-20-03614">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamasue</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kasai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Iwanami</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ohtani</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Abe</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Kuroki</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Fukuda</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sadamatsu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sasaki</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Voxel-based analysis of MRI reveals anterior cingulate gray-matter volume reduction in posttraumatic stress disorder due to terrorism</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2003</year>
<volume>100</volume>
<fpage>9039</fpage>
<lpage>9043</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1530467100</pub-id>
<pub-id pub-id-type="pmid">12853571</pub-id>
</element-citation>
</ref>
<ref id="B30-ijms-20-03614">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Doherty</surname>
<given-names>D.C.</given-names>
</name>
<name>
<surname>Chitty</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Saddiqui</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Lagopoulos</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>A systematic review and meta-analysis of magnetic resonance imaging measurement of structural volumes in posttraumatic stress disorder</article-title>
<source/>Psychiatry Res.
          <year>2015</year>
<volume>232</volume>
<fpage>1</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="doi">10.1016/j.pscychresns.2015.01.002</pub-id>
<pub-id pub-id-type="pmid">25735885</pub-id>
</element-citation>
</ref>
<ref id="B31-ijms-20-03614">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rauch</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Phelps</surname>
<given-names>E.A.</given-names>
</name>
</person-group>
<article-title>Neurocircuitry models of posttraumatic stress disorder and extinction: Human neuroimaging research-past, present, and future</article-title>
<source/>Biol. Psychiatry
          <year>2006</year>
<volume>60</volume>
<fpage>376</fpage>
<lpage>382</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2006.06.004</pub-id>
<pub-id pub-id-type="pmid">16919525</pub-id>
</element-citation>
</ref>
<ref id="B32-ijms-20-03614">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Logue</surname>
<given-names>M.W.</given-names>
</name>
<name>
<surname>van Rooij</surname>
<given-names>S.J.H.</given-names>
</name>
<name>
<surname>Dennis</surname>
<given-names>E.L.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Hayes</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Densmore</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Haswell</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Ipser</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Koch</surname>
<given-names>S.B.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Smaller Hippocampal Volume in Posttraumatic Stress Disorder: A Multisite ENIGMA-PGC Study: Subcortical Volumetry Results From Posttraumatic Stress Disorder Consortia</article-title>
<source/>Biol. Psychiatry
          <year>2018</year>
<volume>83</volume>
<fpage>244</fpage>
<lpage>253</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2017.09.006</pub-id>
<pub-id pub-id-type="pmid">29217296</pub-id>
</element-citation>
</ref>
<ref id="B33-ijms-20-03614">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shin</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>C.I.</given-names>
</name>
<name>
<surname>Cannistraro</surname>
<given-names>P.A.</given-names>
</name>
<name>
<surname>Wedig</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>McMullin</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Martis</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Macklin</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Lasko</surname>
<given-names>N.B.</given-names>
</name>
<name>
<surname>Cavanagh</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Krangel</surname>
<given-names>T.S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A functional magnetic resonance imaging study of amygdala and medial prefrontal cortex responses to overtly presented fearful faces in posttraumatic stress disorder</article-title>
<source/>Arch Gen. Psychiatry
          <year>2005</year>
<volume>62</volume>
<fpage>273</fpage>
<lpage>281</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.62.3.273</pub-id>
<pub-id pub-id-type="pmid">15753240</pub-id>
</element-citation>
</ref>
<ref id="B34-ijms-20-03614">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rauch</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Whalen</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>McInerney</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Macklin</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Lasko</surname>
<given-names>N.B.</given-names>
</name>
<name>
<surname>Orr</surname>
<given-names>S.P.</given-names>
</name>
<name>
<surname>Pitman</surname>
<given-names>R.K.</given-names>
</name>
</person-group>
<article-title>Exaggerated amygdala response to masked facial stimuli in posttraumatic stress disorder: A functional MRI study</article-title>
<source/>Biol. Psychiatry
          <year>2000</year>
<volume>47</volume>
<fpage>769</fpage>
<lpage>776</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-3223(00)00828-3</pub-id>
<pub-id pub-id-type="pmid">10812035</pub-id>
</element-citation>
</ref>
<ref id="B35-ijms-20-03614">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shin</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Whalen</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Pitman</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Bush</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Macklin</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Lasko</surname>
<given-names>N.B.</given-names>
</name>
<name>
<surname>Orr</surname>
<given-names>S.P.</given-names>
</name>
<name>
<surname>McInerney</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Rauch</surname>
<given-names>S.L.</given-names>
</name>
</person-group>
<article-title>An fMRI study of anterior cingulate function in posttraumatic stress disorder</article-title>
<source/>Biol. Psychiatry
          <year>2001</year>
<volume>50</volume>
<fpage>932</fpage>
<lpage>942</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-3223(01)01215-X</pub-id>
<pub-id pub-id-type="pmid">11750889</pub-id>
</element-citation>
</ref>
<ref id="B36-ijms-20-03614">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patel</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Spreng</surname>
<given-names>R.N.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Girard</surname>
<given-names>T.A.</given-names>
</name>
</person-group>
<article-title>Neurocircuitry models of posttraumatic stress disorder and beyond: A meta-analysis of functional neuroimaging studies</article-title>
<source/>Neurosci. Biobehav. Rev.
          <year>2012</year>
<volume>36</volume>
<fpage>2130</fpage>
<lpage>2142</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2012.06.003</pub-id>
<pub-id pub-id-type="pmid">22766141</pub-id>
</element-citation>
</ref>
<ref id="B37-ijms-20-03614">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lanius</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Frewen</surname>
<given-names>P.A.</given-names>
</name>
<name>
<surname>Tursich</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jetly</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>McKinnon</surname>
<given-names>M.C.</given-names>
</name>
</person-group>
<article-title>Restoring large-scale brain networks in PTSD and related disorders: A proposal for neuroscientifically-informed treatment interventions</article-title>
<source/>Eur. J. Psychotraumatol.
          <year>2015</year>
<volume>6</volume>
<fpage>27313</fpage>
<pub-id pub-id-type="doi">10.3402/ejpt.v6.27313</pub-id>
<pub-id pub-id-type="pmid">25854674</pub-id>
</element-citation>
</ref>
<ref id="B38-ijms-20-03614">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hayes</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Hayes</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Mikedis</surname>
<given-names>A.M.</given-names>
</name>
</person-group>
<article-title>Quantitative meta-analysis of neural activity in posttraumatic stress disorder</article-title>
<source/>Biol. Mood Anxiety Disord.
          <year>2012</year>
<volume>2</volume>
<fpage>9</fpage>
<pub-id pub-id-type="doi">10.1186/2045-5380-2-9</pub-id>
<pub-id pub-id-type="pmid">22738125</pub-id>
</element-citation>
</ref>
<ref id="B39-ijms-20-03614">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koch</surname>
<given-names>S.B.</given-names>
</name>
<name>
<surname>van Zuiden</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nawijn</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Frijling</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Veltman</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Olff</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Aberrant resting-state brain activity in posttraumatic stress disorder: A meta-analysis and systematic review</article-title>
<source/>Depress. Anxiety
          <year>2016</year>
<volume>33</volume>
<fpage>592</fpage>
<lpage>605</lpage>
<pub-id pub-id-type="doi">10.1002/da.22478</pub-id>
<pub-id pub-id-type="pmid">26918313</pub-id>
</element-citation>
</ref>
<ref id="B40-ijms-20-03614">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bremner</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Staib</surname>
<given-names>L.H.</given-names>
</name>
<name>
<surname>Kaloupek</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Southwick</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Soufer</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Charney</surname>
<given-names>D.S.</given-names>
</name>
</person-group>
<article-title>Neural correlates of exposure to traumatic pictures and sound in Vietnam combat veterans with and without posttraumatic stress disorder: A positron emission tomography study</article-title>
<source/>Biol. Psychiatry
          <year>1999</year>
<volume>45</volume>
<fpage>806</fpage>
<lpage>816</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-3223(98)00297-2</pub-id>
<pub-id pub-id-type="pmid">10202567</pub-id>
</element-citation>
</ref>
<ref id="B41-ijms-20-03614">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Memory consolidation of fear conditioning: Bi-stable amygdala connectivity with dorsal anterior cingulate and medial prefrontal cortex</article-title>
<source/>Soc. Cogn. Affect. Neurosci.
          <year>2014</year>
<volume>9</volume>
<fpage>1730</fpage>
<lpage>1737</lpage>
<pub-id pub-id-type="doi">10.1093/scan/nst170</pub-id>
<pub-id pub-id-type="pmid">24194579</pub-id>
</element-citation>
</ref>
<ref id="B42-ijms-20-03614">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jeon</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chetana</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ruley</surname>
<given-names>H.E.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Rabah</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kinet</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>H.S.</given-names>
</name>
</person-group>
<article-title>Observational fear learning involves affective pain system and Cav1.2 Ca2+ channels in ACC</article-title>
<source/>Nat. Neurosci.
          <year>2010</year>
<volume>13</volume>
<fpage>482</fpage>
<lpage>488</lpage>
<pub-id pub-id-type="doi">10.1038/nn.2504</pub-id>
<pub-id pub-id-type="pmid">20190743</pub-id>
</element-citation>
</ref>
<ref id="B43-ijms-20-03614">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mátyás</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>H.S.</given-names>
</name>
<name>
<surname>Acsády</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>The fear circuit of the mouse forebrain: Connections between the mediodorsal thalamus, frontal cortices and basolateral amygdala</article-title>
<source/>Eur. J. Neurosci.
          <year>2014</year>
<volume>39</volume>
<fpage>1810</fpage>
<lpage>1823</lpage>
<pub-id pub-id-type="doi">10.1111/ejn.12610</pub-id>
<pub-id pub-id-type="pmid">24819022</pub-id>
</element-citation>
</ref>
<ref id="B44-ijms-20-03614">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duman</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Girgenti</surname>
<given-names>M.J.</given-names>
</name>
</person-group>
<article-title>Molecular and cellular studies of PTSD: Postmortem transcriptome analysis and novel therapeutic targets</article-title>
<source/>J. Neurosci. Res.
          <year>2019</year>
<volume>97</volume>
<fpage>292</fpage>
<lpage>299</lpage>
<pub-id pub-id-type="doi">10.1002/jnr.24306</pub-id>
<pub-id pub-id-type="pmid">30136735</pub-id>
</element-citation>
</ref>
<ref id="B45-ijms-20-03614">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Myers</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Mechanisms of fear extinction</article-title>
<source/>Mol. Psychiatry
          <year>2007</year>
<volume>12</volume>
<fpage>120</fpage>
<lpage>150</lpage>
<pub-id pub-id-type="doi">10.1038/sj.mp.4001939</pub-id>
<pub-id pub-id-type="pmid">17160066</pub-id>
</element-citation>
</ref>
<ref id="B46-ijms-20-03614">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roy</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Friedlander</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Banks-Williams</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lande</surname>
<given-names>R.G.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Blair</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>McLellan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Law</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Tarpley</surname>
<given-names>V.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Improvement in cerebral function with treatment of posttraumatic stress disorder</article-title>
<source/>Ann. N. Y. Acad. Sci.
          <year>2010</year>
<volume>1208</volume>
<fpage>142</fpage>
<lpage>149</lpage>
<pub-id pub-id-type="doi">10.1111/j.1749-6632.2010.05689.x</pub-id>
<pub-id pub-id-type="pmid">20955336</pub-id>
</element-citation>
</ref>
<ref id="B47-ijms-20-03614">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szeszko</surname>
<given-names>P.R.</given-names>
</name>
<name>
<surname>Yehuda</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Magnetic resonance imaging predictors of psychotherapy treatment response in post-traumatic stress disorder: A role for the salience network</article-title>
<source/>Psychiatry Res.
          <year>2019</year>
<volume>277</volume>
<fpage>52</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="doi">10.1016/j.psychres.2019.02.005</pub-id>
<pub-id pub-id-type="pmid">30755338</pub-id>
</element-citation>
</ref>
<ref id="B48-ijms-20-03614">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flanagan</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Hand</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jarnecke</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Moran-Santa Maria</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Brady</surname>
<given-names>K.T.</given-names>
</name>
<name>
<surname>Joseph</surname>
<given-names>J.E.</given-names>
</name>
</person-group>
<article-title>Effects of oxytocin on working memory and executive control system connectivity in posttraumatic stress disorder</article-title>
<source/>Exp. Clin. Psychopharmacol.
          <year>2018</year>
<volume>26</volume>
<fpage>391</fpage>
<lpage>402</lpage>
<pub-id pub-id-type="doi">10.1037/pha0000197</pub-id>
<pub-id pub-id-type="pmid">30070567</pub-id>
</element-citation>
</ref>
<ref id="B49-ijms-20-03614">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bossini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tavanti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lombardelli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Calossi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Polizzotto</surname>
<given-names>N.R.</given-names>
</name>
<name>
<surname>Galli</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vatti</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pieraccini</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Castrogiovanni</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Changes in hippocampal volume in patients with post-traumatic stress disorder after sertraline treatment</article-title>
<source/>J. Clin. Psychopharmacol.
          <year>2007</year>
<volume>27</volume>
<fpage>233</fpage>
<lpage>235</lpage>
<pub-id pub-id-type="doi">10.1097/01.jcp.0000264979.09862.a8</pub-id>
<pub-id pub-id-type="pmid">17414261</pub-id>
</element-citation>
</ref>
<ref id="B50-ijms-20-03614">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vermetten</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Vythilingam</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Southwick</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Charney</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Bremner</surname>
<given-names>J.D.</given-names>
</name>
</person-group>
<article-title>Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder</article-title>
<source/>Biol. Psychiatry
          <year>2003</year>
<volume>54</volume>
<fpage>693</fpage>
<lpage>702</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-3223(03)00634-6</pub-id>
<pub-id pub-id-type="pmid">14512209</pub-id>
</element-citation>
</ref>
<ref id="B51-ijms-20-03614">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Letizia</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Andrea</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Paolo</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Neuroanatomical changes after eye movement desensitization and reprocessing (EMDR) treatment in posttraumatic stress disorder</article-title>
<source/>J. Neuropsychiatry Clin. Neurosci.
          <year>2007</year>
<volume>19</volume>
<fpage>475</fpage>
<lpage>476</lpage>
<pub-id pub-id-type="doi">10.1176/jnp.2007.19.4.475</pub-id>
<pub-id pub-id-type="pmid">18070859</pub-id>
</element-citation>
</ref>
<ref id="B52-ijms-20-03614">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nardo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Högberg</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Looi</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Larsson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hällström</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pagani</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Gray matter density in limbic and paralimbic cortices is associated with trauma load and EMDR outcome in PTSD patients</article-title>
<source/>J. Psychiatry Res.
          <year>2010</year>
<volume>44</volume>
<fpage>477</fpage>
<lpage>485</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2009.10.014</pub-id>
<pub-id pub-id-type="pmid">19942229</pub-id>
</element-citation>
</ref>
<ref id="B53-ijms-20-03614">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bryant</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Felmingham</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Whitford</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Kemp</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Peduto</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>L.M.</given-names>
</name>
</person-group>
<article-title>Rostral anterior cingulate volume predicts treatment response to cognitive-behavioural therapy for posttraumatic stress disorder</article-title>
<source/>J. Psychiatry Neurosci.
          <year>2008</year>
<volume>33</volume>
<fpage>142</fpage>
<lpage>146</lpage>
<pub-id pub-id-type="doi">10.1017/s0033291707002231</pub-id>
<pub-id pub-id-type="pmid">18330460</pub-id>
</element-citation>
</ref>
<ref id="B54-ijms-20-03614">
<label>54.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<collab>National Institute for Clinical Excellence (NICE)</collab>
</person-group>
<source/>Post-Traumatic Stress Disorder: Management (CG26)
          <publisher-name>National Institute for Health and Clinical Excellence</publisher-name>
<publisher-loc>Manchester, UK</publisher-loc>
<year>2005</year>
</element-citation>
</ref>
<ref id="B55-ijms-20-03614">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kar</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Cognitive behavioral therapy for the treatment of post-traumatic stress disorder: A review</article-title>
<source/>Neuropsychiatry Dis. Treat.
          <year>2011</year>
<volume>7</volume>
<fpage>167</fpage>
<lpage>181</lpage>
<pub-id pub-id-type="doi">10.2147/NDT.S10389</pub-id>
<pub-id pub-id-type="pmid">21552319</pub-id>
</element-citation>
</ref>
<ref id="B56-ijms-20-03614">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Schnitzlein</surname>
<given-names>C.W.</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Vythilingam</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rasmusson</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Hoge</surname>
<given-names>C.W.</given-names>
</name>
</person-group>
<article-title>Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: Systemic review and meta-analyses to determine first-line treatments</article-title>
<source/>Depress. Anxiety
          <year>2016</year>
<volume>33</volume>
<fpage>792</fpage>
<lpage>806</lpage>
<pub-id pub-id-type="doi">10.1002/da.22511</pub-id>
<pub-id pub-id-type="pmid">27126398</pub-id>
</element-citation>
</ref>
<ref id="B57-ijms-20-03614">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Resick</surname>
<given-names>P.A.</given-names>
</name>
<name>
<surname>Nishith</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Weaver</surname>
<given-names>T.L.</given-names>
</name>
<name>
<surname>Astin</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Feuer</surname>
<given-names>C.A.</given-names>
</name>
</person-group>
<article-title>A comparison of cognitive-processing therapy with prolonged exposure and a waiting condition for the treatment of chronic posttraumatic stress disorder in female rape victims</article-title>
<source/>J. Consult. Clin. Psychol.
          <year>2002</year>
<volume>70</volume>
<fpage>867</fpage>
<lpage>879</lpage>
<pub-id pub-id-type="doi">10.1037/0022-006X.70.4.867</pub-id>
<pub-id pub-id-type="pmid">12182270</pub-id>
</element-citation>
</ref>
<ref id="B58-ijms-20-03614">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Asukai</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tsuruta</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kishimoto</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nishikawa</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Efficacy of exposure therapy for Japanese patients with posttraumatic stress disorder due to mixed traumatic events: A randomized controlled study</article-title>
<source/>J. Trauma Stress
          <year>2010</year>
<volume>23</volume>
<fpage>744</fpage>
<lpage>750</lpage>
<pub-id pub-id-type="doi">10.1002/jts.20589</pub-id>
<pub-id pub-id-type="pmid">21171135</pub-id>
</element-citation>
</ref>
<ref id="B59-ijms-20-03614">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monson</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Fredman</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Macdonald</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pukay-Martin</surname>
<given-names>N.D.</given-names>
</name>
<name>
<surname>Resick</surname>
<given-names>P.A.</given-names>
</name>
<name>
<surname>Schnurr</surname>
<given-names>P.P.</given-names>
</name>
</person-group>
<article-title>Effect of cognitive-behavioral couple therapy for PTSD: A randomized controlled trial</article-title>
<source/>JAMA
          <year>2012</year>
<volume>308</volume>
<fpage>700</fpage>
<lpage>709</lpage>
<pub-id pub-id-type="doi">10.1001/jama.2012.9307</pub-id>
<pub-id pub-id-type="pmid">22893167</pub-id>
</element-citation>
</ref>
<ref id="B60-ijms-20-03614">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hollifield</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sinclair-Lian</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Warner</surname>
<given-names>T.D.</given-names>
</name>
<name>
<surname>Hammerschlag</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Acupuncture for posttraumatic stress disorder: A randomized controlled pilot trial</article-title>
<source/>J. Nerv. Ment. Dis.
          <year>2007</year>
<volume>195</volume>
<fpage>504</fpage>
<lpage>513</lpage>
<pub-id pub-id-type="doi">10.1097/NMD.0b013e31803044f8</pub-id>
<pub-id pub-id-type="pmid">17568299</pub-id>
</element-citation>
</ref>
<ref id="B61-ijms-20-03614">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ehlers</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hackmann</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Grey</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wild</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liness</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Albert</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Deale</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Stott</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>D.M.</given-names>
</name>
</person-group>
<article-title>A randomized controlled trial of 7-day intensive and standard weekly cognitive therapy for PTSD and emotion-focused supportive therapy</article-title>
<source/>Am. J. Psychiatry
          <year>2014</year>
<volume>171</volume>
<fpage>294</fpage>
<lpage>304</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.2013.13040552</pub-id>
<pub-id pub-id-type="pmid">24480899</pub-id>
</element-citation>
</ref>
<ref id="B62-ijms-20-03614">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ter Heide</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Mooren</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>van de Schoot</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>de Jongh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kleber</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Eye movement desensitisation and reprocessing therapy v. stabilisation as usual for refugees: Randomised controlled trial</article-title>
<source/>Br. J. Psychiatry
          <year>2016</year>
<volume>209</volume>
<fpage>311</fpage>
<lpage>318</lpage>
<pub-id pub-id-type="doi">10.1192/bjp.bp.115.167775</pub-id>
<pub-id pub-id-type="pmid">26892849</pub-id>
</element-citation>
</ref>
<ref id="B63-ijms-20-03614">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carlson</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Chemtob</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Rusnak</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hedlund</surname>
<given-names>N.L.</given-names>
</name>
<name>
<surname>Muraoka</surname>
<given-names>M.Y.</given-names>
</name>
</person-group>
<article-title>Eye movement desensitization and reprocessing (EDMR) treatment for combat-related posttraumatic stress disorder</article-title>
<source/>J. Trauma Stress
          <year>1998</year>
<volume>11</volume>
<fpage>3</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="doi">10.1023/A:1024448814268</pub-id>
<pub-id pub-id-type="pmid">9479673</pub-id>
</element-citation>
</ref>
<ref id="B64-ijms-20-03614">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Kolk</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Spinazzola</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Blaustein</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Hopper</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Hopper</surname>
<given-names>E.K.</given-names>
</name>
<name>
<surname>Korn</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Simpson</surname>
<given-names>W.B.</given-names>
</name>
</person-group>
<article-title>A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: Treatment effects and long-term maintenance</article-title>
<source/>J. Clin. Psychiatry
          <year>2007</year>
<volume>68</volume>
<fpage>37</fpage>
<lpage>46</lpage>
<pub-id pub-id-type="doi">10.4088/JCP.v68n0105</pub-id>
<pub-id pub-id-type="pmid">17284128</pub-id>
</element-citation>
</ref>
<ref id="B65-ijms-20-03614">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krakow</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hollifield</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Johnston</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Koss</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schrader</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Warner</surname>
<given-names>T.D.</given-names>
</name>
<name>
<surname>Tandberg</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lauriello</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>McBride</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cutchen</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Imagery rehearsal therapy for chronic nightmares in sexual assault survivors with posttraumatic stress disorder: A randomized controlled trial</article-title>
<source/>JAMA
          <year>2001</year>
<volume>286</volume>
<fpage>537</fpage>
<lpage>545</lpage>
<pub-id pub-id-type="doi">10.1001/jama.286.5.537</pub-id>
<pub-id pub-id-type="pmid">11476655</pub-id>
</element-citation>
</ref>
<ref id="B66-ijms-20-03614">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boden</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Kimerling</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jacobs-Lentz</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bowman</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Weaver</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Carney</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Walser</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Trafton</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Seeking Safety treatment for male veterans with a substance use disorder and post-traumatic stress disorder symptomatology</article-title>
<source/>Addiction
          <year>2012</year>
<volume>107</volume>
<fpage>578</fpage>
<lpage>586</lpage>
<pub-id pub-id-type="doi">10.1111/j.1360-0443.2011.03658.x</pub-id>
<pub-id pub-id-type="pmid">21923756</pub-id>
</element-citation>
</ref>
<ref id="B67-ijms-20-03614">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galovski</surname>
<given-names>T.E.</given-names>
</name>
<name>
<surname>Blain</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Mott</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Elwood</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Houle</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Manualized therapy for PTSD: Flexing the structure of cognitive processing therapy</article-title>
<source/>J. Consult. Clin. Psychol.
          <year>2012</year>
<volume>80</volume>
<fpage>968</fpage>
<lpage>981</lpage>
<pub-id pub-id-type="doi">10.1037/a0030600</pub-id>
<pub-id pub-id-type="pmid">23106761</pub-id>
</element-citation>
</ref>
<ref id="B68-ijms-20-03614">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martenyi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>E.B.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Prakash</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Koke</surname>
<given-names>S.C.</given-names>
</name>
</person-group>
<article-title>Fluoxetine versus placebo in posttraumatic stress disorder</article-title>
<source/>J. Clin. Psychiatry
          <year>2002</year>
<volume>63</volume>
<fpage>199</fpage>
<lpage>206</lpage>
<pub-id pub-id-type="doi">10.4088/JCP.v63n0305</pub-id>
<pub-id pub-id-type="pmid">11926718</pub-id>
</element-citation>
</ref>
<ref id="B69-ijms-20-03614">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Kolk</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Dreyfuss</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Michaels</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shera</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Berkowitz</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fisler</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Saxe</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Fluoxetine in posttraumatic stress disorder</article-title>
<source/>J. Clin. Psychiatry
          <year>1994</year>
<volume>55</volume>
<fpage>517</fpage>
<lpage>522</lpage>
<pub-id pub-id-type="pmid">7814344</pub-id>
</element-citation>
</ref>
<ref id="B70-ijms-20-03614">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martenyi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>E.B.</given-names>
</name>
<name>
<surname>Caldwell</surname>
<given-names>C.D.</given-names>
</name>
</person-group>
<article-title>Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: Results of a fixed-dose, placebo-controlled study</article-title>
<source/>J. Clin. Psychopharmacol.
          <year>2007</year>
<volume>27</volume>
<fpage>166</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="doi">10.1097/JCP.0b013e31803308ce</pub-id>
<pub-id pub-id-type="pmid">17414240</pub-id>
</element-citation>
</ref>
<ref id="B71-ijms-20-03614">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marshall</surname>
<given-names>R.D.</given-names>
</name>
<name>
<surname>Beebe</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Oldham</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zaninelli</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study</article-title>
<source/>Am. J. Psychiatry
          <year>2001</year>
<volume>158</volume>
<fpage>1982</fpage>
<lpage>1988</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.158.12.1982</pub-id>
<pub-id pub-id-type="pmid">11729013</pub-id>
</element-citation>
</ref>
<ref id="B72-ijms-20-03614">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tucker</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zaninelli</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yehuda</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ruggiero</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dillingham</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pitts</surname>
<given-names>C.D.</given-names>
</name>
</person-group>
<article-title>Paroxetine in the treatment of chronic posttraumatic stress disorder: Results of a placebo-controlled, flexible-dosage trial</article-title>
<source/>J. Clin. Psychiatry
          <year>2001</year>
<volume>62</volume>
<fpage>860</fpage>
<lpage>868</lpage>
<pub-id pub-id-type="doi">10.4088/JCP.v62n1105</pub-id>
<pub-id pub-id-type="pmid">11775045</pub-id>
</element-citation>
</ref>
<ref id="B73-ijms-20-03614">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brady</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pearlstein</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Asnis</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rothbaum</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sikes</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Farfel</surname>
<given-names>G.M.</given-names>
</name>
</person-group>
<article-title>Efficacy and safety of sertraline treatment of posttraumatic stress disorder: A randomized controlled trial</article-title>
<source/>JAMA
          <year>2000</year>
<volume>283</volume>
<fpage>1837</fpage>
<lpage>1844</lpage>
<pub-id pub-id-type="doi">10.1001/jama.283.14.1837</pub-id>
<pub-id pub-id-type="pmid">10770145</pub-id>
</element-citation>
</ref>
<ref id="B74-ijms-20-03614">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davidson</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Rothbaum</surname>
<given-names>B.O.</given-names>
</name>
<name>
<surname>van der Kolk</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Sikes</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Farfel</surname>
<given-names>G.M.</given-names>
</name>
</person-group>
<article-title>Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder</article-title>
<source/>Arch. Gen. Psychiatry
          <year>2001</year>
<volume>58</volume>
<fpage>485</fpage>
<lpage>492</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.58.5.485</pub-id>
<pub-id pub-id-type="pmid">11343529</pub-id>
</element-citation>
</ref>
<ref id="B75-ijms-20-03614">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zohar</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Amital</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Miodownik</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kotler</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bleich</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lane</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Austin</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder</article-title>
<source/>J. Clin. Psychopharmacol.
          <year>2002</year>
<volume>22</volume>
<fpage>190</fpage>
<lpage>195</lpage>
<pub-id pub-id-type="doi">10.1097/00004714-200204000-00013</pub-id>
<pub-id pub-id-type="pmid">11910265</pub-id>
</element-citation>
</ref>
<ref id="B76-ijms-20-03614">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davidson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rothbaum</surname>
<given-names>B.O.</given-names>
</name>
<name>
<surname>Tucker</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Asnis</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Benattia</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Musgnung</surname>
<given-names>J.J.</given-names>
</name>
</person-group>
<article-title>Venlafaxine extended release in posttraumatic stress disorder: A sertraline- and placebo-controlled study</article-title>
<source/>J. Clin. Psychopharmacol.
          <year>2006</year>
<volume>26</volume>
<fpage>259</fpage>
<lpage>267</lpage>
<pub-id pub-id-type="doi">10.1097/01.jcp.0000222514.71390.c1</pub-id>
<pub-id pub-id-type="pmid">16702890</pub-id>
</element-citation>
</ref>
<ref id="B77-ijms-20-03614">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davidson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Baldwin</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Kuper</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Benattia</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Musgnung</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Treatment of posttraumatic stress disorder with venlafaxine extended release: A 6-month randomized controlled trial</article-title>
<source/>Arch. Gen. Psychiatry
          <year>2006</year>
<volume>63</volume>
<fpage>1158</fpage>
<lpage>1165</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.63.10.1158</pub-id>
<pub-id pub-id-type="pmid">17015818</pub-id>
</element-citation>
</ref>
<ref id="B78-ijms-20-03614">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kosten</surname>
<given-names>T.R.</given-names>
</name>
<name>
<surname>Frank</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Dan</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>McDougle</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Giller</surname>
<given-names>E.L.</given-names>
<suffix>Jr.</suffix>
</name>
</person-group>
<article-title>Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine</article-title>
<source/>J. Nerv. Ment. Dis.
          <year>1991</year>
<volume>179</volume>
<fpage>366</fpage>
<lpage>370</lpage>
<pub-id pub-id-type="doi">10.1097/00005053-199106000-00011</pub-id>
<pub-id pub-id-type="pmid">2051152</pub-id>
</element-citation>
</ref>
<ref id="B79-ijms-20-03614">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davidson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kudler</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mahorney</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Lipper</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hammett</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Saunders</surname>
<given-names>W.B.</given-names>
</name>
<name>
<surname>Cavenar</surname>
<given-names>J.O.</given-names>
<suffix>Jr.</suffix>
</name>
</person-group>
<article-title>Treatment of posttraumatic stress disorder with amitriptyline and placebo</article-title>
<source/>Arch. Gen. Psychiatry
          <year>1990</year>
<volume>47</volume>
<fpage>259</fpage>
<lpage>266</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.1990.01810150059010</pub-id>
<pub-id pub-id-type="pmid">2407208</pub-id>
</element-citation>
</ref>
<ref id="B80-ijms-20-03614">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davidson</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Weisler</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Butterfield</surname>
<given-names>M.I.</given-names>
</name>
<name>
<surname>Casat</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Connor</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Barnett</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>van Meter</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Mirtazapine vs. placebo in posttraumatic stress disorder: A pilot trial</article-title>
<source/>Biol. Psychiatry
          <year>2003</year>
<volume>53</volume>
<fpage>188</fpage>
<lpage>191</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-3223(02)01411-7</pub-id>
<pub-id pub-id-type="pmid">12547477</pub-id>
</element-citation>
</ref>
<ref id="B81-ijms-20-03614">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Becker</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Hertzberg</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Dennis</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Bukenya</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Beckham</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder</article-title>
<source/>J. Clin. Psychopharmacol.
          <year>2007</year>
<volume>27</volume>
<fpage>193</fpage>
<lpage>197</lpage>
<pub-id pub-id-type="doi">10.1097/JCP.0b013e318032eaed</pub-id>
<pub-id pub-id-type="pmid">17414245</pub-id>
</element-citation>
</ref>
<ref id="B82-ijms-20-03614">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamner</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Faldowski</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Ulmer</surname>
<given-names>H.G.</given-names>
</name>
<name>
<surname>Frueh</surname>
<given-names>B.C.</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Arana</surname>
<given-names>G.W.</given-names>
</name>
</person-group>
<article-title>Adjunctive risperidone treatment in post-traumatic stress disorder: A preliminary controlled trial of effects on comorbid psychotic symptoms</article-title>
<source/>Int. Clin. Psychopharmacol.
          <year>2003</year>
<volume>18</volume>
<fpage>1</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1097/00004850-200301000-00001</pub-id>
<pub-id pub-id-type="pmid">12490768</pub-id>
</element-citation>
</ref>
<ref id="B83-ijms-20-03614">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reich</surname>
<given-names>D.B.</given-names>
</name>
<name>
<surname>Winternitz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hennen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Watts</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Stanculescu</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women</article-title>
<source/>J. Clin. Psychiatry
          <year>2004</year>
<volume>65</volume>
<fpage>1601</fpage>
<lpage>1606</lpage>
<pub-id pub-id-type="doi">10.4088/JCP.v65n1204</pub-id>
<pub-id pub-id-type="pmid">15641864</pub-id>
</element-citation>
</ref>
<ref id="B84-ijms-20-03614">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krystal</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Rosenheck</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Cramer</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Vessicchio</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Vertrees</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Horney</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>G.D.</given-names>
</name>
<name>
<surname>Stock</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Veterans, Affairs, Cooperative, Study, No. 504 Group. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: A randomized trial</article-title>
<source/>JAMA
          <year>2011</year>
<volume>306</volume>
<fpage>493</fpage>
<lpage>502</lpage>
<pub-id pub-id-type="doi">10.1001/jama.2011.1080</pub-id>
<pub-id pub-id-type="pmid">21813427</pub-id>
</element-citation>
</ref>
<ref id="B85-ijms-20-03614">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stein</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Kline</surname>
<given-names>N.A.</given-names>
</name>
<name>
<surname>Matloff</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>Adjunctive olanzapine for SSRI-resistant combat-related PTSD: A double-blind, placebo-controlled study</article-title>
<source/>Am. J. Psychiatry
          <year>2002</year>
<volume>159</volume>
<fpage>1777</fpage>
<lpage>1779</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.159.10.1777</pub-id>
<pub-id pub-id-type="pmid">12359687</pub-id>
</element-citation>
</ref>
<ref id="B86-ijms-20-03614">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carey</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Suliman</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ganesan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Seedat</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>D.J.</given-names>
</name>
</person-group>
<article-title>Olanzapine monotherapy in posttraumatic stress disorder: Efficacy in a randomized, double-blind, placebo-controlled study</article-title>
<source/>Hum. Psychopharmacol.
          <year>2012</year>
<volume>27</volume>
<fpage>386</fpage>
<lpage>391</lpage>
<pub-id pub-id-type="doi">10.1002/hup.2238</pub-id>
<pub-id pub-id-type="pmid">22730105</pub-id>
</element-citation>
</ref>
<ref id="B87-ijms-20-03614">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lambert</surname>
<given-names>M.T.</given-names>
</name>
</person-group>
<article-title>Aripiprazole in the management of post-traumatic stress disorder symptoms in returning Global War on Terrorism veterans</article-title>
<source/>Int. Clin. Psychopharmacol.
          <year>2006</year>
<volume>21</volume>
<fpage>185</fpage>
<lpage>187</lpage>
<pub-id pub-id-type="doi">10.1097/01.yic.0000185021.48279.00</pub-id>
<pub-id pub-id-type="pmid">16528142</pub-id>
</element-citation>
</ref>
<ref id="B88-ijms-20-03614">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamner</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Brodrick</surname>
<given-names>P.S.</given-names>
</name>
<name>
<surname>Labbate</surname>
<given-names>L.A.</given-names>
</name>
</person-group>
<article-title>Gabapentin in PTSD: A retrospective, clinical series of adjunctive therapy</article-title>
<source/>Ann. Clin. Psychiatry
          <year>2001</year>
<volume>13</volume>
<fpage>141</fpage>
<lpage>146</lpage>
<pub-id pub-id-type="doi">10.3109/10401230109148960</pub-id>
<pub-id pub-id-type="pmid">11791951</pub-id>
</element-citation>
</ref>
<ref id="B89-ijms-20-03614">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raskind</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Peskind</surname>
<given-names>E.R.</given-names>
</name>
<name>
<surname>Kanter</surname>
<given-names>E.D.</given-names>
</name>
<name>
<surname>Petrie</surname>
<given-names>E.C.</given-names>
</name>
<name>
<surname>Radant</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Dobie</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Hoff</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rein</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Straits-Tröster</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: A placebo-controlled study</article-title>
<source/>Am. J. Psychiatry
          <year>2003</year>
<volume>160</volume>
<fpage>371</fpage>
<lpage>373</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.160.2.371</pub-id>
<pub-id pub-id-type="pmid">12562588</pub-id>
</element-citation>
</ref>
<ref id="B90-ijms-20-03614">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raskind</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hoff</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Hart</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Homas</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Daniels</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Calohan</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan</article-title>
<source/>Am. J. Psychiatry
          <year>2013</year>
<volume>170</volume>
<fpage>1003</fpage>
<lpage>1010</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.2013.12081133</pub-id>
<pub-id pub-id-type="pmid">23846759</pub-id>
</element-citation>
</ref>
<ref id="B91-ijms-20-03614">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raskind</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Peskind</surname>
<given-names>E.R.</given-names>
</name>
<name>
<surname>Chow</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Davis-Karim</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>H.A.</given-names>
</name>
<name>
<surname>Hart</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>McFall</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mellman</surname>
<given-names>T.A.</given-names>
</name>
<name>
<surname>Reist</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans</article-title>
<source/>N. Engl. J. Med.
          <year>2018</year>
<volume>378</volume>
<fpage>507</fpage>
<lpage>517</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1507598</pub-id>
<pub-id pub-id-type="pmid">29414272</pub-id>
</element-citation>
</ref>
<ref id="B92-ijms-20-03614">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tucker</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Trautman</surname>
<given-names>R.P.</given-names>
</name>
<name>
<surname>Wyatt</surname>
<given-names>D.B.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Capece</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Rosenthal</surname>
<given-names>N.R.</given-names>
</name>
</person-group>
<article-title>Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: A randomized, double-blind, placebo-controlled study</article-title>
<source/>J. Clin. Psychiatry
          <year>2007</year>
<volume>68</volume>
<fpage>201</fpage>
<lpage>206</lpage>
<pub-id pub-id-type="doi">10.4088/JCP.v68n0204</pub-id>
<pub-id pub-id-type="pmid">17335317</pub-id>
</element-citation>
</ref>
<ref id="B93-ijms-20-03614">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yeh</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Mari</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Andreoli</surname>
<given-names>S.B.</given-names>
</name>
<name>
<surname>Bressan</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Mello</surname>
<given-names>M.F.</given-names>
</name>
</person-group>
<article-title>A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD</article-title>
<source/>CNS Neurosci. Ther.
          <year>2011</year>
<volume>17</volume>
<fpage>305</fpage>
<lpage>310</lpage>
<pub-id pub-id-type="doi">10.1111/j.1755-5949.2010.00188.x</pub-id>
<pub-id pub-id-type="pmid">21554564</pub-id>
</element-citation>
</ref>
<ref id="B94-ijms-20-03614">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jetly</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Heber</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fraser</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Boisvert</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study</article-title>
<source/>Psychoneuroendocrinology
          <year>2015</year>
<volume>51</volume>
<fpage>585</fpage>
<lpage>588</lpage>
<pub-id pub-id-type="doi">10.1016/j.psyneuen.2014.11.002</pub-id>
<pub-id pub-id-type="pmid">25467221</pub-id>
</element-citation>
</ref>
<ref id="B95-ijms-20-03614">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gunduz-Cinar</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Flynn</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Brockway</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kaugars</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Baldi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ramikie</surname>
<given-names>T.S.</given-names>
</name>
<name>
<surname>Cinar</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kunos</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Fluoxetine Facilitates Fear Extinction Through Amygdala Endocannabinoids</article-title>
<source/>Neuropsychopharmacology
          <year>2016</year>
<volume>41</volume>
<fpage>1598</fpage>
<lpage>1609</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2015.318</pub-id>
<pub-id pub-id-type="pmid">26514583</pub-id>
</element-citation>
</ref>
<ref id="B96-ijms-20-03614">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deschaux</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Spennato</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Moreau</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Chronic treatment with fluoxetine prevents the return of extinguished auditory-cued conditioned fear</article-title>
<source/>Psychopharmacology
          <year>2011</year>
<volume>215</volume>
<fpage>231</fpage>
<lpage>237</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-010-2134-y</pub-id>
<pub-id pub-id-type="pmid">21181120</pub-id>
</element-citation>
</ref>
<ref id="B97-ijms-20-03614">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bentefour</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Rakibi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Bennis</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ba-M’hamed</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Paroxetine treatment, following behavioral suppression of PTSD-like symptoms in mice, prevents relapse by activating the infralimbic cortex</article-title>
<source/>Eur. Neuropsychopharmacol.
          <year>2016</year>
<volume>26</volume>
<fpage>195</fpage>
<lpage>207</lpage>
<pub-id pub-id-type="doi">10.1016/j.euroneuro.2015.12.021</pub-id>
<pub-id pub-id-type="pmid">26706692</pub-id>
</element-citation>
</ref>
<ref id="B98-ijms-20-03614">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alvarez-Ricartes</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Oliveros-Matus</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mendoza</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Perez-Urrutia</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Echeverria</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Iarkov</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Barreto</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>Echeverria</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Intranasal Cotinine Plus Krill Oil Facilitates Fear Extinction, Decreases Depressive-Like Behavior, and Increases Hippocampal Calcineurin A Levels in Mice</article-title>
<source/>Mol. Neurobiol.
          <year>2018</year>
<volume>55</volume>
<fpage>7949</fpage>
<lpage>7960</lpage>
<pub-id pub-id-type="doi">10.1007/s12035-018-0916-0</pub-id>
<pub-id pub-id-type="pmid">29488138</pub-id>
</element-citation>
</ref>
<ref id="B99-ijms-20-03614">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>H.S.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>W.L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>L.L.</given-names>
</name>
<name>
<surname>Si</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Suo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>Venlafaxine facilitates between-session extinction and prevents reinstatement of auditory-cue conditioned fear</article-title>
<source/>Behav. Brain Res.
          <year>2012</year>
<volume>230</volume>
<fpage>268</fpage>
<lpage>273</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2012.02.023</pub-id>
<pub-id pub-id-type="pmid">22366271</pub-id>
</element-citation>
</ref>
<ref id="B100-ijms-20-03614">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kakui</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Yokoyama</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yamauchi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kitamura</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Imanishi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Koyama</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Anxiolytic-like profile of mirtazapine in rat conditioned fear stress model: Functional significance of 5-hydroxytryptamine 1A receptor and alpha1-adrenergic receptor</article-title>
<source/>Pharmacol. Biochem. Behav.
          <year>2009</year>
<volume>92</volume>
<fpage>393</fpage>
<lpage>398</lpage>
<pub-id pub-id-type="doi">10.1016/j.pbb.2008.12.022</pub-id>
<pub-id pub-id-type="pmid">19167420</pub-id>
</element-citation>
</ref>
<ref id="B101-ijms-20-03614">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>An</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kitaichi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nakagawa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kusumi</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Combined treatment with subchronic lithium and acute intracerebral mirtazapine microinjection into the median raphe nucleus exerted an anxiolytic-like effect synergistically</article-title>
<source/>Eur. J. Pharmacol.
          <year>2016</year>
<volume>783</volume>
<fpage>112</fpage>
<lpage>116</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejphar.2016.05.004</pub-id>
<pub-id pub-id-type="pmid">27154172</pub-id>
</element-citation>
</ref>
<ref id="B102-ijms-20-03614">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Anxiolytic-like property of risperidone and olanzapine as examined in multiple measures of fear in rats</article-title>
<source/>Pharmacol. Biochem. Behav.
          <year>2010</year>
<volume>95</volume>
<fpage>298</fpage>
<lpage>307</lpage>
<pub-id pub-id-type="doi">10.1016/j.pbb.2010.02.005</pub-id>
<pub-id pub-id-type="pmid">20167232</pub-id>
</element-citation>
</ref>
<ref id="B103-ijms-20-03614">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Milstein</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Elnabawi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vinish</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Swanson</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Enos</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Kolb</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Frost</surname>
<given-names>D.O.</given-names>
</name>
</person-group>
<article-title>Olanzapine treatment of adolescent rats causes enduring specific memory impairments and alters cortical development and function</article-title>
<source/>PLoS ONE
          <year>2013</year>
<volume>8</volume>
<elocation-id>e57308</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0057308</pub-id>
<pub-id pub-id-type="pmid">23437365</pub-id>
</element-citation>
</ref>
<ref id="B104-ijms-20-03614">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ganella</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Lee-Kardashyan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Luikinga</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>D.L.D.</given-names>
</name>
<name>
<surname>Madsen</surname>
<given-names>H.B.</given-names>
</name>
<name>
<surname>Zbukvic</surname>
<given-names>I.C.</given-names>
</name>
<name>
<surname>Coulthard</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lawrence</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.H.</given-names>
</name>
</person-group>
<article-title>Aripiprazole Facilitates Extinction of Conditioned Fear in Adolescent Rats</article-title>
<source/>Front. Behav. Neurosci.
          <year>2017</year>
<volume>11</volume>
<fpage>76</fpage>
<pub-id pub-id-type="doi">10.3389/fnbeh.2017.00076</pub-id>
<pub-id pub-id-type="pmid">28536511</pub-id>
</element-citation>
</ref>
<ref id="B105-ijms-20-03614">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dubrovina</surname>
<given-names>N.I.</given-names>
</name>
<name>
<surname>Zinov’eva</surname>
<given-names>D.V.</given-names>
</name>
</person-group>
<article-title>Effects of activation and blockade of dopamine receptors on the extinction of a passive avoidance reaction in mice with a depressive-like state</article-title>
<source/>Neurosci. Behav. Physiol.
          <year>2010</year>
<volume>40</volume>
<fpage>55</fpage>
<lpage>59</lpage>
<pub-id pub-id-type="doi">10.1007/s11055-009-9226-3</pub-id>
<pub-id pub-id-type="pmid">20012492</pub-id>
</element-citation>
</ref>
<ref id="B106-ijms-20-03614">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicolas</surname>
<given-names>L.B.</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Prinssen</surname>
<given-names>E.P.</given-names>
</name>
</person-group>
<article-title>Defensive-like behaviors induced by ultrasound: Further pharmacological characterization in Lister-hooded rats</article-title>
<source/>Psychopharmacology
          <year>2007</year>
<volume>194</volume>
<fpage>243</fpage>
<lpage>252</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-007-0838-4</pub-id>
<pub-id pub-id-type="pmid">17589832</pub-id>
</element-citation>
</ref>
<ref id="B107-ijms-20-03614">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gazarini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Stern</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Carobrez</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Bertoglio</surname>
<given-names>L.J.</given-names>
</name>
</person-group>
<article-title>Enhanced noradrenergic activity potentiates fear memory consolidation and reconsolidation by differentially recruiting α1- and β-adrenergic receptors</article-title>
<source/>Learn. Mem.
          <year>2013</year>
<volume>20</volume>
<fpage>210</fpage>
<lpage>219</lpage>
<pub-id pub-id-type="doi">10.1101/lm.030007.112</pub-id>
<pub-id pub-id-type="pmid">23512937</pub-id>
</element-citation>
</ref>
<ref id="B108-ijms-20-03614">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lucas</surname>
<given-names>E.K.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>W.C.</given-names>
</name>
<name>
<surname>Roman-Ortiz</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Clem</surname>
<given-names>R.L.</given-names>
</name>
</person-group>
<article-title>Prazosin during fear conditioning facilitates subsequent extinction in male C57Bl/6N mice</article-title>
<source/>Psychopharmacology
          <year>2018</year>
<volume>236</volume>
<fpage>273</fpage>
<lpage>279</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-018-5001-x</pub-id>
<pub-id pub-id-type="pmid">30112577</pub-id>
</element-citation>
</ref>
<ref id="B109-ijms-20-03614">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmidt do Prado-Lima</surname>
<given-names>P.A.</given-names>
</name>
<name>
<surname>Perrenoud</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Kristensen</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Cammarota</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Izquierdo</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Topiramate diminishes fear memory consolidation and extinguishes conditioned fear in rats</article-title>
<source/>J. Psychiatry Neurosci.
          <year>2011</year>
<volume>36</volume>
<fpage>250</fpage>
<lpage>255</lpage>
<pub-id pub-id-type="doi">10.1503/jpn.100115</pub-id>
<pub-id pub-id-type="pmid">21392483</pub-id>
</element-citation>
</ref>
<ref id="B110-ijms-20-03614">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rau</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>DeCola</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Fanselow</surname>
<given-names>M.S.</given-names>
</name>
</person-group>
<article-title>Stress-induced enhancement of fear learning: An animal model of posttraumatic stress disorder</article-title>
<source/>Neurosci. Biobehav. Rev.
          <year>2005</year>
<volume>29</volume>
<fpage>1207</fpage>
<lpage>1223</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2005.04.010</pub-id>
<pub-id pub-id-type="pmid">16095698</pub-id>
</element-citation>
</ref>
<ref id="B111-ijms-20-03614">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liberzon</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Krstov</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>E.A.</given-names>
</name>
</person-group>
<article-title>Stress-restress: Effects on ACTH and fast feedback</article-title>
<source/>Psychoneuroendocrinology
          <year>1997</year>
<volume>22</volume>
<fpage>443</fpage>
<lpage>453</lpage>
<pub-id pub-id-type="doi">10.1016/S0306-4530(97)00044-9</pub-id>
<pub-id pub-id-type="pmid">9364622</pub-id>
</element-citation>
</ref>
<ref id="B112-ijms-20-03614">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vanderheyden</surname>
<given-names>W.M.</given-names>
</name>
<name>
<surname>George</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Urpa</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kehoe</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liberzon</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Poe</surname>
<given-names>G.R.</given-names>
</name>
</person-group>
<article-title>Sleep alterations following exposure to stress predict fear-associated memory impairments in a rodent model of PTSD</article-title>
<source/>Exp. Brain Res.
          <year>2015</year>
<volume>233</volume>
<fpage>2335</fpage>
<lpage>2346</lpage>
<pub-id pub-id-type="doi">10.1007/s00221-015-4302-0</pub-id>
<pub-id pub-id-type="pmid">26019008</pub-id>
</element-citation>
</ref>
<ref id="B113-ijms-20-03614">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Change of Rin1 and Stathmin in the animal model of traumatic stresses</article-title>
<source/>Front. Behav. Neurosci.
          <year>2017</year>
<volume>11</volume>
<fpage>62</fpage>
<pub-id pub-id-type="doi">10.3389/fnbeh.2017.00062</pub-id>
<pub-id pub-id-type="pmid">28491025</pub-id>
</element-citation>
</ref>
<ref id="B114-ijms-20-03614">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iwamoto</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Morinobu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yamawaki</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Single prolonged stress increases contextual freezing and the expression of glycine transporter 1 and vesicle-associated membrane protein 2 mRNA in the hippocampus of rats</article-title>
<source/>Prog. Neuro-Psychopharmacol. Biol. Psychiatry
          <year>2007</year>
<volume>31</volume>
<fpage>642</fpage>
<lpage>651</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2006.12.010</pub-id>
<pub-id pub-id-type="pmid">17267088</pub-id>
</element-citation>
</ref>
<ref id="B115-ijms-20-03614">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keller</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Schreiber</surname>
<given-names>W.B.</given-names>
</name>
<name>
<surname>Stanfield</surname>
<given-names>B.R.</given-names>
</name>
<name>
<surname>Knox</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Inhibiting corticosterone synthesis during fear memory formation exacerbates cued fear extinction memory deficits within the single prolonged stress model</article-title>
<source/>Behav. Brain Res.
          <year>2015</year>
<volume>287</volume>
<fpage>182</fpage>
<lpage>186</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2015.03.043</pub-id>
<pub-id pub-id-type="pmid">25839906</pub-id>
</element-citation>
</ref>
<ref id="B116-ijms-20-03614">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zoladz</surname>
<given-names>P.R.</given-names>
</name>
<name>
<surname>Conrad</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Fleshner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Diamond</surname>
<given-names>D.M.</given-names>
</name>
</person-group>
<article-title>Acute episodes of predator exposure in conjunction with chronic social instability as an animal model of post-traumatic stress disorder</article-title>
<source/>Stress
          <year>2008</year>
<volume>11</volume>
<fpage>259</fpage>
<lpage>281</lpage>
<pub-id pub-id-type="doi">10.1080/10253890701768613</pub-id>
<pub-id pub-id-type="pmid">18574787</pub-id>
</element-citation>
</ref>
<ref id="B117-ijms-20-03614">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zoladz</surname>
<given-names>P.R.</given-names>
</name>
<name>
<surname>Fleshner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Diamond</surname>
<given-names>D.M.</given-names>
</name>
</person-group>
<article-title>Psychosocial animal model of PTSD produces a long-lasting traumatic memory, an increase in general anxiety and PTSD-like glucocorticoid abnormalities</article-title>
<source/>Psychoneuroendocrinology
          <year>2012</year>
<volume>37</volume>
<fpage>1531</fpage>
<lpage>1545</lpage>
<pub-id pub-id-type="doi">10.1016/j.psyneuen.2012.02.007</pub-id>
<pub-id pub-id-type="pmid">22421563</pub-id>
</element-citation>
</ref>
<ref id="B118-ijms-20-03614">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zohar</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>An animal model of posttraumatic stress disorder: The use of cut-off behavioral criteria</article-title>
<source/>Ann. N. Y. Acad. Sci.
          <year>2004</year>
<volume>1032</volume>
<fpage>167</fpage>
<lpage>178</lpage>
<pub-id pub-id-type="doi">10.1196/annals.1314.014</pub-id>
<pub-id pub-id-type="pmid">15677404</pub-id>
</element-citation>
</ref>
<ref id="B119-ijms-20-03614">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daskalakis</surname>
<given-names>N.P.</given-names>
</name>
<name>
<surname>Yehuda</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Diamond</surname>
<given-names>D.M.</given-names>
</name>
</person-group>
<article-title>Animal models in translational studies of PTSD</article-title>
<source/>Psychoneuroendocrinology
          <year>2013</year>
<volume>38</volume>
<fpage>1895</fpage>
<lpage>1911</lpage>
<pub-id pub-id-type="doi">10.1016/j.psyneuen.2013.06.006</pub-id>
<pub-id pub-id-type="pmid">23845512</pub-id>
</element-citation>
</ref>
<ref id="B120-ijms-20-03614">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maren</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Stress and Fear Extinction</article-title>
<source/>Neuropsychopharmacology
          <year>2016</year>
<volume>41</volume>
<fpage>58</fpage>
<lpage>79</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2015.180</pub-id>
<pub-id pub-id-type="pmid">26105142</pub-id>
</element-citation>
</ref>
<ref id="B121-ijms-20-03614">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parks</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>P.S.</given-names>
</name>
<name>
<surname>Sibille</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Shenk</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Toth</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Increased anxiety of mice lacking the serotonin1A receptor</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>1998</year>
<volume>95</volume>
<fpage>10734</fpage>
<lpage>10739</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.95.18.10734</pub-id>
<pub-id pub-id-type="pmid">9724773</pub-id>
</element-citation>
</ref>
<ref id="B122-ijms-20-03614">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holmes</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Lesch</surname>
<given-names>K.P.</given-names>
</name>
<name>
<surname>Crawley</surname>
<given-names>J.N.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>D.L.</given-names>
</name>
</person-group>
<article-title>Mice lacking the serotonin transporter exhibit 5-HT(1A) receptor-mediated abnormalities in tests for anxiety-like behavior</article-title>
<source/>Neuropsychopharmacology
          <year>2003</year>
<volume>28</volume>
<fpage>2077</fpage>
<lpage>2088</lpage>
<pub-id pub-id-type="doi">10.1038/sj.npp.1300266</pub-id>
<pub-id pub-id-type="pmid">12968128</pub-id>
</element-citation>
</ref>
<ref id="B123-ijms-20-03614">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klemenhagen</surname>
<given-names>K.C.</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>David</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Hen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Gross</surname>
<given-names>C.T.</given-names>
</name>
</person-group>
<article-title>Increased fear response to contextual cues in mice lacking the 5-HT1A receptor</article-title>
<source/>Neuropsychopharmacology
          <year>2006</year>
<volume>31</volume>
<fpage>101</fpage>
<lpage>111</lpage>
<pub-id pub-id-type="doi">10.1038/sj.npp.1300774</pub-id>
<pub-id pub-id-type="pmid">15920501</pub-id>
</element-citation>
</ref>
<ref id="B124-ijms-20-03614">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wellman</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Izquierdo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Garrett</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>K.P.</given-names>
</name>
<name>
<surname>Carroll</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Millstein</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lesch</surname>
<given-names>K.P.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Impaired stress-coping and fear extinction and abnormal corticolimbic morphology in serotonin transporter knock-out mice</article-title>
<source/>J. Neurosci.
          <year>2007</year>
<volume>27</volume>
<fpage>684</fpage>
<lpage>691</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.4595-06.2007</pub-id>
<pub-id pub-id-type="pmid">17234600</pub-id>
</element-citation>
</ref>
<ref id="B125-ijms-20-03614">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adamec</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Burton</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Blundell</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Vulnerability to mild predator stress in serotonin transporter knockout mice</article-title>
<source/>Behav. Brain Res.
          <year>2006</year>
<volume>170</volume>
<fpage>126</fpage>
<lpage>140</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2006.02.012</pub-id>
<pub-id pub-id-type="pmid">16546269</pub-id>
</element-citation>
</ref>
<ref id="B126-ijms-20-03614">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacobsen</surname>
<given-names>K.X.</given-names>
</name>
<name>
<surname>Czesak</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Deria</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Le François</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Albert</surname>
<given-names>P.R.</given-names>
</name>
</person-group>
<article-title>Region-specific regulation of 5-HT1A receptor expression by Pet-1-dependent mechanisms in vivo</article-title>
<source/>J. Neurochem.
          <year>2011</year>
<volume>116</volume>
<fpage>1066</fpage>
<lpage>1076</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2010.07161.x</pub-id>
<pub-id pub-id-type="pmid">21182526</pub-id>
</element-citation>
</ref>
<ref id="B127-ijms-20-03614">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hendricks</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Fyodorov</surname>
<given-names>D.V.</given-names>
</name>
<name>
<surname>Wegman</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Lelutiu</surname>
<given-names>N.B.</given-names>
</name>
<name>
<surname>Pehek</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Silver</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Weeber</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Sweatt</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Deneris</surname>
<given-names>E.S.</given-names>
</name>
</person-group>
<article-title>Pet-1 ETS gene plays a critical role in 5-HT neuron development and is required for normal anxiety-like and aggressive behavior</article-title>
<source/>Neuron
          <year>2003</year>
<volume>37</volume>
<fpage>233</fpage>
<lpage>247</lpage>
<pub-id pub-id-type="doi">10.1016/S0896-6273(02)01167-4</pub-id>
<pub-id pub-id-type="pmid">12546819</pub-id>
</element-citation>
</ref>
<ref id="B128-ijms-20-03614">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wellman</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Camp</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>V.M.</given-names>
</name>
<name>
<surname>MacPherson</surname>
<given-names>K.P.</given-names>
</name>
<name>
<surname>Ihne</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fitzgerald</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Maroun</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Drabant</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bogdan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hariri</surname>
<given-names>A.R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Convergent effects of mouse Pet-1 deletion and human PET-1 variation on amygdala fear and threat processing</article-title>
<source/>Exp. Neurol.
          <year>2013</year>
<volume>250</volume>
<fpage>260</fpage>
<lpage>269</lpage>
<pub-id pub-id-type="doi">10.1016/j.expneurol.2013.09.025</pub-id>
<pub-id pub-id-type="pmid">24100022</pub-id>
</element-citation>
</ref>
<ref id="B129-ijms-20-03614">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Pattwell</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jing</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Bath</surname>
<given-names>K.G.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>F.S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.Y.</given-names>
</name>
</person-group>
<article-title>Variant BDNF Val66Met polymorphism affects extinction of conditioned aversive memory</article-title>
<source/>J. Neurosci.
          <year>2009</year>
<volume>29</volume>
<fpage>4056</fpage>
<lpage>4064</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.5539-08.2009</pub-id>
<pub-id pub-id-type="pmid">19339601</pub-id>
</element-citation>
</ref>
<ref id="B130-ijms-20-03614">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Somerville</surname>
<given-names>L.H.</given-names>
</name>
<name>
<surname>Voss</surname>
<given-names>H.U.</given-names>
</name>
<name>
<surname>Glover</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ballon</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Liston</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Teslovich</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Van Kempen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>F.S.</given-names>
</name>
<name>
<surname>Casey</surname>
<given-names>B.J.</given-names>
</name>
</person-group>
<article-title>A genetic variant BDNF polymorphism alters extinction learning in both mouse and human</article-title>
<source/>Science
          <year>2010</year>
<volume>327</volume>
<fpage>863</fpage>
<lpage>866</lpage>
<pub-id pub-id-type="doi">10.1126/science.1181886</pub-id>
<pub-id pub-id-type="pmid">20075215</pub-id>
</element-citation>
</ref>
<ref id="B131-ijms-20-03614">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thoeringer</surname>
<given-names>C.K.</given-names>
</name>
<name>
<surname>Henes</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Eder</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dahlhoff</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wurst</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Holsboer</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Deussing</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Moosmang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wotjak</surname>
<given-names>C.T.</given-names>
</name>
</person-group>
<article-title>Consolidation of remote fear memories involves Corticotropin-Releasing Hormone (CRH) receptor type 1-mediated enhancement of AMPA receptor GluR1 signaling in the dentate gyrus</article-title>
<source/>Neuropsychopharmacology
          <year>2012</year>
<volume>37</volume>
<fpage>787</fpage>
<lpage>796</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2011.256</pub-id>
<pub-id pub-id-type="pmid">22030710</pub-id>
</element-citation>
</ref>
<ref id="B132-ijms-20-03614">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verma</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tasan</surname>
<given-names>R.O.</given-names>
</name>
<name>
<surname>Herzog</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sperk</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>NPY controls fear conditioning and fear extinction by combined action on Y₁ and Y₂ receptors</article-title>
<source/>Br. J. Pharmacol.
          <year>2012</year>
<volume>166</volume>
<fpage>1461</fpage>
<lpage>1473</lpage>
<pub-id pub-id-type="doi">10.1111/j.1476-5381.2012.01872.x</pub-id>
<pub-id pub-id-type="pmid">22289084</pub-id>
</element-citation>
</ref>
<ref id="B133-ijms-20-03614">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joseph</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mamiya</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L.L.</given-names>
</name>
<name>
<surname>Jiao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y.P.</given-names>
</name>
</person-group>
<article-title>Temporal association of elevated cholecystokininergic tone and adolescent trauma is critical for posttraumatic stress disorder-like behavior in adult mice</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2013</year>
<volume>110</volume>
<fpage>6589</fpage>
<lpage>6594</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1219601110</pub-id>
<pub-id pub-id-type="pmid">23576730</pub-id>
</element-citation>
</ref>
<ref id="B134-ijms-20-03614">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gordon</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Nutrition and cognitive function</article-title>
<source/>Brain Dev.
          <year>1997</year>
<volume>19</volume>
<fpage>165</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="doi">10.1016/S0387-7604(96)00560-8</pub-id>
<pub-id pub-id-type="pmid">9134186</pub-id>
</element-citation>
</ref>
<ref id="B135-ijms-20-03614">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sakayori</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kikkawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tokuda</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kiryu</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Yoshizaki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kawashima</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Arai</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>J.X.</given-names>
</name>
<name>
<surname>Katagiri</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Maternal dietary imbalance between omega-6 and omega-3 polyunsaturated fatty acids impairs neocortical development via epoxy metabolites</article-title>
<source/>Stem Cells
          <year>2016</year>
<volume>34</volume>
<fpage>470</fpage>
<lpage>482</lpage>
<pub-id pub-id-type="doi">10.1002/stem.2246</pub-id>
<pub-id pub-id-type="pmid">26580686</pub-id>
</element-citation>
</ref>
<ref id="B136-ijms-20-03614">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arvindakshan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ghate</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ranjekar</surname>
<given-names>P.K.</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Mahadik</surname>
<given-names>S.P.</given-names>
</name>
</person-group>
<article-title>Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia</article-title>
<source/>Schizophr. Res.
          <year>2003</year>
<volume>62</volume>
<fpage>195</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="doi">10.1016/S0920-9964(02)00284-0</pub-id>
<pub-id pub-id-type="pmid">12837515</pub-id>
</element-citation>
</ref>
<ref id="B137-ijms-20-03614">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vancassel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Durand</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Barthélémy</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lejeune</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Martineau</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Guilloteau</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Andrès</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chalon</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Plasma fatty acid levels in autistic children</article-title>
<source/>Prostaglandins Leukot. Essent. Fatty Acids
          <year>2011</year>
<volume>65</volume>
<fpage>1</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1054/plef.2001.0281</pub-id>
<pub-id pub-id-type="pmid">11487301</pub-id>
</element-citation>
</ref>
<ref id="B138-ijms-20-03614">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maekawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Takashima</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Matsumata</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ikegami</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kontani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hara</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kawashima</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Owada</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kiso</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yoshikawa</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Arachidonic acid drives postnatal neurogenesis and elicits a beneficial effect on prepulse inhibition, a biological trait of psychiatric illnesses</article-title>
<source/>PLoS ONE
          <year>2009</year>
<volume>4</volume>
<elocation-id>e5085</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0005085</pub-id>
<pub-id pub-id-type="pmid">19352438</pub-id>
</element-citation>
</ref>
<ref id="B139-ijms-20-03614">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Vries</surname>
<given-names>G.J.</given-names>
</name>
<name>
<surname>Mocking</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lok</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Assies</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Schene</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Olff</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Fatty acid concentrations in patients with posttraumatic stress disorder compared to healthy controls</article-title>
<source/>J. Affect. Disord.
          <year>2016</year>
<volume>205</volume>
<fpage>351</fpage>
<lpage>359</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2016.08.021</pub-id>
<pub-id pub-id-type="pmid">27567082</pub-id>
</element-citation>
</ref>
<ref id="B140-ijms-20-03614">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsuoka</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nishi</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Nakaya</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sone</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hamazaki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hamazaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Koido</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Attenuating posttraumatic distress with omega-3 polyunsaturated fatty acids among disaster medical assistance team members after the Great East Japan Earthquake: The APOP randomized controlled trial</article-title>
<source/>BMC Psychiatry
          <year>2011</year>
<volume>11</volume>
<elocation-id>132</elocation-id>
<pub-id pub-id-type="doi">10.1186/1471-244X-11-132</pub-id>
<pub-id pub-id-type="pmid">21846343</pub-id>
</element-citation>
</ref>
<ref id="B141-ijms-20-03614">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsuoka</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Clearance of fear memory from the hippocampus through neurogenesis by omega-3 fatty acids: A novel preventive strategy for posttraumatic stress disorder?</article-title>
<source/>Biopsychosoc. Med.
          <year>2011</year>
<volume>5</volume>
<fpage>3</fpage>
<pub-id pub-id-type="doi">10.1186/1751-0759-5-3</pub-id>
<pub-id pub-id-type="pmid">21303552</pub-id>
</element-citation>
</ref>
<ref id="B142-ijms-20-03614">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsuoka</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nishi</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yonemoto</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hamazaki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hamazaki</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Omega-3 fatty acids for secondary prevention of posttraumatic stress disorder after accidental injury: An open-label pilot study</article-title>
<source/>J. Clin. Psychopharmacol.
          <year>2010</year>
<volume>30</volume>
<fpage>217</fpage>
<lpage>219</lpage>
<pub-id pub-id-type="doi">10.1097/JCP.0b013e3181d48830</pub-id>
<pub-id pub-id-type="pmid">20520307</pub-id>
</element-citation>
</ref>
<ref id="B143-ijms-20-03614">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kitamura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Saitoh</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Takashima</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Murayama</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Niibori</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ageta</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sekiguchi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sugiyama</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Inokuchi</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Adult neurogenesis modulates the hippocampus-dependent period of associative fear memory</article-title>
<source/>Cell
          <year>2009</year>
<volume>139</volume>
<fpage>814</fpage>
<lpage>827</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2009.10.020</pub-id>
<pub-id pub-id-type="pmid">19914173</pub-id>
</element-citation>
</ref>
<ref id="B144-ijms-20-03614">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jansen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zerbi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Arnoldussen</surname>
<given-names>I.A.</given-names>
</name>
<name>
<surname>Wiesmann</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rijpma</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>X.T.</given-names>
</name>
<name>
<surname>Dederen</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Mutsaers</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Broersen</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Lütjohann</surname>
<given-names>D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effects of specific multi-nutrient enriched diets on cerebral metabolism, cognition and neuropathology in AβPPswe-PS1dE9 mice</article-title>
<source/>PLoS ONE
          <year>2013</year>
<volume>8</volume>
<elocation-id>e75393</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0075393</pub-id>
<pub-id pub-id-type="pmid">24086523</pub-id>
</element-citation>
</ref>
<ref id="B145-ijms-20-03614">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawakita</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shido</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Docosahexaenoic acid promotes neurogenesis in vitro and in vivo</article-title>
<source/>Neuroscience
          <year>2006</year>
<volume>139</volume>
<fpage>991</fpage>
<lpage>997</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2006.01.021</pub-id>
<pub-id pub-id-type="pmid">16527422</pub-id>
</element-citation>
</ref>
<ref id="B146-ijms-20-03614">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>R.Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Godbout</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>A novel fatty acid-binding protein (FABP) gene resulting from tandem gene duplication in mammals: Transcription in rat retina and testis</article-title>
<source/>Genomics
          <year>2008</year>
<volume>92</volume>
<fpage>436</fpage>
<lpage>445</lpage>
<pub-id pub-id-type="doi">10.1016/j.ygeno.2008.08.003</pub-id>
<pub-id pub-id-type="pmid">18786628</pub-id>
</element-citation>
</ref>
<ref id="B147-ijms-20-03614">
<label>147.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Furuhashi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hotamisligil</surname>
<given-names>G.S.</given-names>
</name>
</person-group>
<article-title>Fatty acid-binding proteins: Role in metabolic diseases and potential as drug targets</article-title>
<source/>Nat. Rev. Drug Discov.
          <year>2008</year>
<volume>7</volume>
<fpage>489</fpage>
<lpage>503</lpage>
<pub-id pub-id-type="doi">10.1038/nrd2589</pub-id>
<pub-id pub-id-type="pmid">18511927</pub-id>
</element-citation>
</ref>
<ref id="B148-ijms-20-03614">
<label>148.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Owada</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yoshimoto</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kondo</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Spatio-temporally differential expression of genes for three members of fatty acid binding proteins in developing and mature rat brains</article-title>
<source/>J. Chem. Neuroanat.
          <year>1996</year>
<volume>12</volume>
<fpage>113</fpage>
<lpage>122</lpage>
<pub-id pub-id-type="doi">10.1016/S0891-0618(96)00192-5</pub-id>
<pub-id pub-id-type="pmid">9115666</pub-id>
</element-citation>
</ref>
<ref id="B149-ijms-20-03614">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsumata</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sakayori</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Maekawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Owada</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yoshikawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Osumi</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>The effects of Fabp7 and Fabp5 on postnatal hippocampal neurogenesis in the mouse</article-title>
<source/>Stem Cells
          <year>2012</year>
<volume>30</volume>
<fpage>1532</fpage>
<lpage>1543</lpage>
<pub-id pub-id-type="doi">10.1002/stem.1124</pub-id>
<pub-id pub-id-type="pmid">22581784</pub-id>
</element-citation>
</ref>
<ref id="B150-ijms-20-03614">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Owada</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Abdelwahab</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Kitanaka</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sakagami</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Takano</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sugitani</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sugawara</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kawashima</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kiso</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Mobarakeh</surname>
<given-names>J.I.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Altered emotional behavioral responses in mice lacking brain-type fatty acid-binding protein gene</article-title>
<source/>Eur. J. Neurosci.
          <year>2006</year>
<volume>24</volume>
<fpage>175</fpage>
<lpage>187</lpage>
<pub-id pub-id-type="doi">10.1111/j.1460-9568.2006.04855.x</pub-id>
<pub-id pub-id-type="pmid">16882015</pub-id>
</element-citation>
</ref>
<ref id="B151-ijms-20-03614">
<label>151.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gerstner</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Perron</surname>
<given-names>I.J.</given-names>
</name>
<name>
<surname>Riedy</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Yoshikawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kadotani</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Owada</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Van Dongen</surname>
<given-names>H.P.A.</given-names>
</name>
<name>
<surname>Galnte</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Dickinson</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>J.C.P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Normal sleep requires the astrocyte brain-type fatty acid binding protein FABP7</article-title>
<source/>Sci. Adv.
          <year>2017</year>
<volume>3</volume>
<fpage>e1602663</fpage>
<pub-id pub-id-type="doi">10.1126/sciadv.1602663</pub-id>
<pub-id pub-id-type="pmid">28435883</pub-id>
</element-citation>
</ref>
<ref id="B152-ijms-20-03614">
<label>152.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takeuchi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fukunaga</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Differential subcellular localization of two dopamine D2 receptor isoforms in transfected NG108-15 cells</article-title>
<source/>J. Neurochem.
          <year>2003</year>
<volume>85</volume>
<fpage>1064</fpage>
<lpage>1074</lpage>
<pub-id pub-id-type="doi">10.1046/j.1471-4159.2003.01763.x</pub-id>
<pub-id pub-id-type="pmid">12716438</pub-id>
</element-citation>
</ref>
<ref id="B153-ijms-20-03614">
<label>153.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shioda</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Binas</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Owada</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fukunaga</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Heart-type fatty acid binding protein regulates dopamine D2 receptor function in mouse brain</article-title>
<source/>J. Neurosci.
          <year>2010</year>
<volume>30</volume>
<fpage>3146</fpage>
<lpage>3155</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.4140-09.2010</pub-id>
<pub-id pub-id-type="pmid">20181611</pub-id>
</element-citation>
</ref>
<ref id="B154-ijms-20-03614">
<label>154.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shioda</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Yabuki</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Onozato</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Owada</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fukunaga</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title><italic>FABP3</italic> protein promotes α-synuclein oligomerization associated with 1-methyl-1,2,3,6-tetrahydropiridine-induced neurotoxicity</article-title>
<source/>J. Biol. Chem.
          <year>2014</year>
<volume>289</volume>
<fpage>18957</fpage>
<lpage>18965</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M113.527341</pub-id>
<pub-id pub-id-type="pmid">24855640</pub-id>
</element-citation>
</ref>
<ref id="B155-ijms-20-03614">
<label>155.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shimamoto</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ohnishi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Maekawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ohba</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Arai</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Iwayama</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hisano</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Toyota</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Toyoshima</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Functional characterization of <italic>FABP3</italic>, 5 and 7 gene variants identified in schizophrenia and autism spectrum disorder and mouse behavioral studies</article-title>
<source/>Hum. Mol. Genet.
          <year>2014</year>
<volume>23</volume>
<fpage>6495</fpage>
<lpage>6511</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddu369</pub-id>
<pub-id pub-id-type="pmid">25027319</pub-id>
</element-citation>
</ref>
<ref id="B156-ijms-20-03614">
<label>156.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yabuki</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Takahata</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Matsuo</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Owada</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fukunaga</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Ramelteon Improves Post-traumatic Stress Disorder-Like Behaviors Exhibited by Fatty Acid-Binding Protein 3 Null Mice</article-title>
<source/>Mol. Neurobiol.
          <year>2018</year>
<volume>55</volume>
<fpage>3577</fpage>
<lpage>3591</lpage>
<pub-id pub-id-type="doi">10.1007/s12035-017-0587-2</pub-id>
<pub-id pub-id-type="pmid">28516430</pub-id>
</element-citation>
</ref>
<ref id="B157-ijms-20-03614">
<label>157.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamamoto</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kida</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kagawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yasumoto</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Miyazaki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Islam</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ogata</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yanagawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Mitsushima</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Fukunaga</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>FABP3 in the Anterior Cingulate Cortex Modulates the Methylation Status of the Glutamic Acid Decarboxylase67 Promoter Region</article-title>
<source/>J. Neurosci.
          <year>2018</year>
<volume>38</volume>
<fpage>10411</fpage>
<lpage>10423</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1285-18.2018</pub-id>
<pub-id pub-id-type="pmid">30341178</pub-id>
</element-citation>
</ref>
<ref id="B158-ijms-20-03614">
<label>158.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amaral</surname>
<given-names>O.B.</given-names>
</name>
<name>
<surname>Roesler</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Targeting the NMDA receptor for fear-related disorders</article-title>
<source/>Recent Pat. CNS Drug Discov.
          <year>2008</year>
<volume>3</volume>
<fpage>166</fpage>
<lpage>178</lpage>
<pub-id pub-id-type="doi">10.2174/157488908786242470</pub-id>
<pub-id pub-id-type="pmid">18991806</pub-id>
</element-citation>
</ref>
<ref id="B159-ijms-20-03614">
<label>159.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burgos-Robles</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vidal-Gonzalez</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Santini</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Quirk</surname>
<given-names>G.J.</given-names>
</name>
</person-group>
<article-title>Consolidation of fear extinction requires NMDA receptor-dependent bursting in the ventromedial prefrontal cortex</article-title>
<source/>Neuron
          <year>2007</year>
<volume>53</volume>
<fpage>871</fpage>
<lpage>880</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2007.02.021</pub-id>
<pub-id pub-id-type="pmid">17359921</pub-id>
</element-citation>
</ref>
<ref id="B160-ijms-20-03614">
<label>160.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lerea</surname>
<given-names>L.S.</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>L.S.</given-names>
</name>
<name>
<surname>McNamara</surname>
<given-names>J.O.</given-names>
</name>
</person-group>
<article-title>NMDA and non-NMDA receptor-mediated increase of c-fos mRNA in dentate gyrus neurons involves calcium influx via different routes</article-title>
<source/>J. Neurosci.
          <year>1992</year>
<volume>12</volume>
<fpage>2973</fpage>
<lpage>2981</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.12-08-02973.1992</pub-id>
<pub-id pub-id-type="pmid">1322980</pub-id>
</element-citation>
</ref>
<ref id="B161-ijms-20-03614">
<label>161.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Comai</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gobbi</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: A novel target in psychopharmacology</article-title>
<source/>J. Psychiatry Neurosci.
          <year>2014</year>
<volume>39</volume>
<fpage>6</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1503/jpn.130009</pub-id>
<pub-id pub-id-type="pmid">23971978</pub-id>
</element-citation>
</ref>
<ref id="B162-ijms-20-03614">
<label>162.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doyen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mighiu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kaye</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Colineaux</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Beaumanoir</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mouraeff</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Rieu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Paubel</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Contejean</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Melatonin in children with autistic spectrum disorders: Recent and practical data</article-title>
<source/>Eur. Child Adolesc. Psychiatry
          <year>2011</year>
<volume>20</volume>
<fpage>231</fpage>
<lpage>239</lpage>
<pub-id pub-id-type="doi">10.1007/s00787-011-0162-8</pub-id>
<pub-id pub-id-type="pmid">21359552</pub-id>
</element-citation>
</ref>
<ref id="B163-ijms-20-03614">
<label>163.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.Q.</given-names>
</name>
</person-group>
<article-title>Melatonin facilitates extinction, but not acquisition or expression, of conditional cued fear in rats</article-title>
<source/>BMC Neurosci.
          <year>2014</year>
<volume>15</volume>
<elocation-id>86</elocation-id>
<pub-id pub-id-type="doi">10.1186/1471-2202-15-86</pub-id>
<pub-id pub-id-type="pmid">25026909</pub-id>
</element-citation>
</ref>
<ref id="B164-ijms-20-03614">
<label>164.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishiyama</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Shintani</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hirai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yoshikubo</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Molecular cloning and pharmacological characterization of monkey MT1 and MT2 melatonin receptors showing high affinity for the agonist ramelteon</article-title>
<source/>J. Pharmacol. Exp. Ther.
          <year>2009</year>
<volume>330</volume>
<fpage>855</fpage>
<lpage>863</lpage>
<pub-id pub-id-type="doi">10.1124/jpet.109.155283</pub-id>
<pub-id pub-id-type="pmid">19556449</pub-id>
</element-citation>
</ref>
<ref id="B165-ijms-20-03614">
<label>165.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lacoste</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Angeloni</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dominguez-Lopez</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Calderoni</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mauro</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fraschini</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Descarries</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gobbi</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Anatomical and cellular localization of melatonin MT1 and MT2 receptors in the adult rat brain</article-title>
<source/>J. Pineal Res.
          <year>2015</year>
<volume>58</volume>
<fpage>397</fpage>
<lpage>417</lpage>
<pub-id pub-id-type="doi">10.1111/jpi.12224</pub-id>
<pub-id pub-id-type="pmid">25726952</pub-id>
</element-citation>
</ref>
<ref id="B166-ijms-20-03614">
<label>166.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tian</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yabuki</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Moriguchi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fukunaga</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y.M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>M.H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Melatonin reverses the decreases in hippocampal protein serine/threonine kinases observed in an animal model of autism</article-title>
<source/>J. Pineal Res.
          <year>2014</year>
<volume>56</volume>
<fpage>1</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="doi">10.1111/jpi.12081</pub-id>
<pub-id pub-id-type="pmid">23952810</pub-id>
</element-citation>
</ref>
<ref id="B167-ijms-20-03614">
<label>167.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Mak</surname>
<given-names>D.O.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Foskett</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Muallem</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>A new mode of Ca2+ signaling by G protein-coupled receptors: Gating of IP3 receptor Ca2+ release channels by Gbetagamma</article-title>
<source/>Curr. Biol.
          <year>2003</year>
<volume>13</volume>
<fpage>872</fpage>
<lpage>876</lpage>
<pub-id pub-id-type="doi">10.1016/S0960-9822(03)00330-0</pub-id>
<pub-id pub-id-type="pmid">12747838</pub-id>
</element-citation>
</ref>
<ref id="B168-ijms-20-03614">
<label>168.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Domínguez-Alonso</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Valdés-Tovar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Solís-Chagoyán</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Benítez-King</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Melatonin stimulates dendrite formation and complexity in the hilar zone of the rat hippocampus: Participation of the Ca++/Calmodulin complex</article-title>
<source/>Int. J. Mol. Sci.
          <year>2015</year>
<volume>16</volume>
<fpage>1907</fpage>
<lpage>1927</lpage>
<pub-id pub-id-type="doi">10.3390/ijms16011907</pub-id>
<pub-id pub-id-type="pmid">25603176</pub-id>
</element-citation>
</ref>
<ref id="B169-ijms-20-03614">
<label>169.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fukunaga</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yabuki</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Takahata</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Matsuo</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Neurological mechanism and therapeutic strategy for posttraumatic stress disorders</article-title>
<source/>Nihon Yakurigaku Zasshi
          <year>2018</year>
<volume>152</volume>
<fpage>194</fpage>
<lpage>201</lpage>
<pub-id pub-id-type="doi">10.1254/fpj.152.194</pub-id>
<pub-id pub-id-type="pmid">30298841</pub-id>
</element-citation>
</ref>
<ref id="B170-ijms-20-03614">
<label>170.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ho</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Chik</surname>
<given-names>C.L.</given-names>
</name>
</person-group>
<article-title>Modulation of Aanat gene transcription in the rat pineal gland</article-title>
<source/>J. Neurochem.
          <year>2010</year>
<volume>112</volume>
<fpage>321</fpage>
<lpage>331</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2009.06457.x</pub-id>
<pub-id pub-id-type="pmid">19860854</pub-id>
</element-citation>
</ref>
<ref id="B171-ijms-20-03614">
<label>171.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walker</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Ressler</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>K.T.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats</article-title>
<source/>J. Neurosci.
          <year>2002</year>
<volume>22</volume>
<fpage>2343</fpage>
<lpage>2351</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.22-06-02343.2002</pub-id>
<pub-id pub-id-type="pmid">11896173</pub-id>
</element-citation>
</ref>
<ref id="B172-ijms-20-03614">
<label>172.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ledgerwood</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Richardson</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cranney</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>D-cycloserine facilitates extinction of learned fear: Effects on reacquisition and generalized extinction</article-title>
<source/>Biol. Psychiatry
          <year>2005</year>
<volume>57</volume>
<fpage>841</fpage>
<lpage>847</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2005.01.023</pub-id>
<pub-id pub-id-type="pmid">15820704</pub-id>
</element-citation>
</ref>
<ref id="B173-ijms-20-03614">
<label>173.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Attari</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rajabi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Maracy</surname>
<given-names>M.R.</given-names>
</name>
</person-group>
<article-title>D-cycloserine for treatment of numbing and avoidance in chronic post traumatic stress disorder: A randomized, double blind, clinical trial</article-title>
<source/>J. Res. Med. Sci.
          <year>2014</year>
<volume>19</volume>
<fpage>592</fpage>
<lpage>598</lpage>
<pub-id pub-id-type="pmid">25364356</pub-id>
</element-citation>
</ref>
<ref id="B174-ijms-20-03614">
<label>174.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shukla</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Govitrapong</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Boontem</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Reiter</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Satayavivad</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Mechanisms of Melatonin in Alleviating Alzheimer’s Disease</article-title>
<source/>Curr. Neuropharmacol.
          <year>2017</year>
<volume>15</volume>
<fpage>1010</fpage>
<lpage>1031</lpage>
<pub-id pub-id-type="doi">10.2174/1570159X15666170313123454</pub-id>
<pub-id pub-id-type="pmid">28294066</pub-id>
</element-citation>
</ref>
<ref id="B175-ijms-20-03614">
<label>175.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McFarlane</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Barton</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Briggs</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kennaway</surname>
<given-names>D.J.</given-names>
</name>
</person-group>
<article-title>The relationship between urinary melatonin metabolite excretion and posttraumatic symptoms following traumatic injury</article-title>
<source/>J. Affect. Disord.
          <year>2010</year>
<volume>127</volume>
<fpage>365</fpage>
<lpage>369</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2010.05.002</pub-id>
<pub-id pub-id-type="pmid">20554012</pub-id>
</element-citation>
</ref>
<ref id="B176-ijms-20-03614">
<label>176.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agorastos</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Linthorst</surname>
<given-names>A.C.</given-names>
</name>
</person-group>
<article-title>Potential pleiotropic beneficial effects of adjuvant melatonergic treatment in posttraumatic stress disorder</article-title>
<source/>J. Pineal Res.
          <year>2016</year>
<volume>61</volume>
<fpage>3</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="doi">10.1111/jpi.12330</pub-id>
<pub-id pub-id-type="pmid">27061919</pub-id>
</element-citation>
</ref>
<ref id="B177-ijms-20-03614">
<label>177.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>R T Ramirez</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Poling</surname>
<given-names>M.I.</given-names>
</name>
<name>
<surname>deCourten</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Chamberlain</surname>
<given-names>R.L.</given-names>
</name>
</person-group>
<article-title>Potential positive feedback loop of pineal cyst and posttraumatic stress disorder</article-title>
<source/>Med. Hypotheses
          <year>2017</year>
<volume>100</volume>
<fpage>87</fpage>
<lpage>88</lpage>
<pub-id pub-id-type="doi">10.1016/j.mehy.2017.01.021</pub-id>
<pub-id pub-id-type="pmid">28236855</pub-id>
</element-citation>
</ref>
<ref id="B178-ijms-20-03614">
<label>178.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alvira</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tajes</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Verdaguer</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Acuña-Castroviejo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Folch</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Camins</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pallas</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson’s disease</article-title>
<source/>J. Pineal Res.
          <year>2006</year>
<volume>40</volume>
<fpage>251</fpage>
<lpage>258</lpage>
<pub-id pub-id-type="doi">10.1111/j.1600-079X.2005.00308.x</pub-id>
<pub-id pub-id-type="pmid">16499562</pub-id>
</element-citation>
</ref>
<ref id="B179-ijms-20-03614">
<label>179.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sase</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Lombroso</surname>
<given-names>S.I.</given-names>
</name>
<name>
<surname>Santhumayor</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>R.R.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Neve</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Heller</surname>
<given-names>E.A.</given-names>
</name>
</person-group>
<article-title>Sex-Specific Regulation of Fear Memory by Targeted Epigenetic Editing of Cdk5</article-title>
<source/>Biol. Psychiatry
          <year>2019</year>
<volume>85</volume>
<fpage>623</fpage>
<lpage>634</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2018.11.022</pub-id>
<pub-id pub-id-type="pmid">30661667</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="ijms-20-03614-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Experimental apparatus and design for evaluation of fear extinction. (<bold>A</bold>) Schematic diagram of contextual fear memory in passive avoidance task to evaluate fear extinction in the mouse. (<bold>B</bold>) Experimental schedule for assessment of fear extinction. Mice received an electric shock (0.5 mA for 3 s) once a day for four consecutive days (fear acquisition). After that, the mouse was exposed to the light box, and step-through latency was measured without an electric shock (fear extinction). D: Day.</p>
</caption>
<graphic xlink:href="ijms-20-03614-g001"></graphic>
</fig>
<fig id="ijms-20-03614-f002" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>Impaired fear extinction processing in <italic>Fabp3</italic> null mice. (<bold>A</bold>) Overview of fear responses as elapsed time during the acquisition (Day 1 to 4) and extinction phase (Day 5 to 35) (<italic>n</italic> = 4–11 per group). (<bold>B</bold>) Ramelteon (1.0 mg/kg, p.o.) repaired the impaired fear extinction process in <italic>Fabp3</italic> null mice from Day 15 to 35, an effect prevented by luzindole (2.5 mg/kg, i.p.) treatment (<italic>n</italic> = 4–11 per group). Error bars represent SEM. * <italic>p</italic> &lt; 0.05 vs. vehicle-treated wild-type (WT) mice; ** <italic>p</italic> &lt; 0.01 vs. vehicle-treated WT mice; # <italic>p</italic> &lt; 0.05 vs. vehicle-treated <italic>Fabp3</italic> null mice; ## <italic>p</italic> &lt; 0.01 vs. vehicle-treated <italic>Fabp3</italic> null mice; † <italic>p</italic> &lt; 0.05 vs. ramelteon (1.0 mg/kg, p.o.)-treated <italic>Fabp3</italic> null mice. Luz, luzindole (2.5 mg/kg, i.p.) treatment; Ram 1.0, ramelteon (1.0 mg/kg, p.o.) treatment; veh, vehicle treatment. Modified data derived from Reference [<xref ref-type="bibr" rid="B156-ijms-20-03614">156</xref>].</p>
</caption>
<graphic xlink:href="ijms-20-03614-g002"></graphic>
</fig>
<fig id="ijms-20-03614-f003" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<p>Aberrant c-Fos expression and CaMKII autophosphorylation levels in the basolateral amygdala (BLA) in <italic>Fabp3</italic> null mice. (<bold>A</bold>) Representative images of BLA in each group of mice one hour after the extinction test on Day 35. The effect of ramelteon (1.0 mg/kg, p.o.) on the elevated level of c-Fos was antagonized by luzindole (2.5 mg/kg, i.p.) treatment in <italic>Fabp3</italic> null mice. Scale bars: 100 µm. (<bold>B</bold>) Representative images of BLA in WT and <italic>Fabp3</italic> null mice stained by phosphorylated CaMKII (red) and c-Fos (green). Increased c-Fos expression levels were observed in elevated autophosphorylation CaMKII-positive cells in BLA of <italic>Fabp3</italic> null mice. Modified data derived from Reference [<xref ref-type="bibr" rid="B156-ijms-20-03614">156</xref>].</p>
</caption>
<graphic xlink:href="ijms-20-03614-g003"></graphic>
</fig>
<fig id="ijms-20-03614-f004" orientation="portrait" position="float">
<label>Figure 4</label>
<caption>
<p>The hypothesis of neuronal circuits in the fear extinction in WT and <italic>Fabp3</italic> null mice. (Left) Contextual fear memory is acquired in the hippocampus and then consolidated and retrieved in the BLA. The ACC negatively regulates neuronal activity in BLA, resulting in suppression of exacerbated fear retrieval and facilitation of fear extinction in WT mice. (Right) Hypofunction in the ACC fails to inhibit aberrant neuronal activity in the BLA, leading to the development of aberrant fear retrieval and impaired fear extinction in <italic>Fabp3</italic> null mice. Ramelteon improves decreased neuronal activity in the ACC through stimulation of the melatonin receptors. Therefore, ramelteon improves the impaired fear extinction by suppressing hyperactivation of BLA in <italic>Fabp3</italic> null mice (Right). Modified data derived from Reference [<xref ref-type="bibr" rid="B170-ijms-20-03614">170</xref>].</p>
</caption>
<graphic xlink:href="ijms-20-03614-g004"></graphic>
</fig>
<table-wrap id="ijms-20-03614-t001" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-20-03614-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>Effects of clinical drugs in patients with post-traumatic stress disorder (PTSD) and animal models of PTSD.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Drug Treatment</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Effects on PTSD Symptoms</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Animal Models</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>SSRI</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Fluoxetine</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Improvement [<xref ref-type="bibr" rid="B64-ijms-20-03614">64</xref>,<xref ref-type="bibr" rid="B68-ijms-20-03614">68</xref>,<xref ref-type="bibr" rid="B69-ijms-20-03614">69</xref>], Not effective [<xref ref-type="bibr" rid="B70-ijms-20-03614">70</xref>]</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Facilitation of fear extinction [<xref ref-type="bibr" rid="B95-ijms-20-03614">95</xref>,<xref ref-type="bibr" rid="B96-ijms-20-03614">96</xref>] </td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Paroxetine</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Improvement [<xref ref-type="bibr" rid="B71-ijms-20-03614">71</xref>,<xref ref-type="bibr" rid="B72-ijms-20-03614">72</xref>] </td>
<td align="center" colspan="1" rowspan="1" valign="middle">Prevention of PTSD symptoms reactivation [<xref ref-type="bibr" rid="B97-ijms-20-03614">97</xref>] </td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Sertraline</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Improvement [<xref ref-type="bibr" rid="B73-ijms-20-03614">73</xref>,<xref ref-type="bibr" rid="B74-ijms-20-03614">74</xref>,<xref ref-type="bibr" rid="B75-ijms-20-03614">75</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">No effect on fear extinction [<xref ref-type="bibr" rid="B98-ijms-20-03614">98</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>SNRI</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Venlafaxine</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Improvement [<xref ref-type="bibr" rid="B76-ijms-20-03614">76</xref>,<xref ref-type="bibr" rid="B77-ijms-20-03614">77</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Facilitation of fear extinction [<xref ref-type="bibr" rid="B99-ijms-20-03614">99</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Anti-depressant</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Mirtazapine</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Improvement [<xref ref-type="bibr" rid="B80-ijms-20-03614">80</xref>], Not effective [<xref ref-type="bibr" rid="B18-ijms-20-03614">18</xref>]</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Relief of fear response [<xref ref-type="bibr" rid="B100-ijms-20-03614">100</xref>,<xref ref-type="bibr" rid="B101-ijms-20-03614">101</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Bupropion</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Not effective [<xref ref-type="bibr" rid="B81-ijms-20-03614">81</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Relief of fear response [<xref ref-type="bibr" rid="B100-ijms-20-03614">100</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Antipsychotics</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Risperidone </td>
<td align="center" colspan="1" rowspan="1" valign="middle">Improvement [<xref ref-type="bibr" rid="B82-ijms-20-03614">82</xref>,<xref ref-type="bibr" rid="B83-ijms-20-03614">83</xref>,<xref ref-type="bibr" rid="B84-ijms-20-03614">84</xref>] </td>
<td align="center" colspan="1" rowspan="1" valign="middle">Facilitation of fear extinction [<xref ref-type="bibr" rid="B102-ijms-20-03614">102</xref>] </td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Olanzapine </td>
<td align="center" colspan="1" rowspan="1" valign="middle">Improvement [<xref ref-type="bibr" rid="B85-ijms-20-03614">85</xref>,<xref ref-type="bibr" rid="B86-ijms-20-03614">86</xref>] </td>
<td align="center" colspan="1" rowspan="1" valign="middle">Relief of fear response [<xref ref-type="bibr" rid="B102-ijms-20-03614">102</xref>], deficits of fear extinction [<xref ref-type="bibr" rid="B103-ijms-20-03614">103</xref>] </td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Aripiprazole</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Improvement [<xref ref-type="bibr" rid="B87-ijms-20-03614">87</xref>]</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Facilitation of fear extinction [<xref ref-type="bibr" rid="B104-ijms-20-03614">104</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Sulpiride</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">No data</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Facilitation of fear extinction [<xref ref-type="bibr" rid="B105-ijms-20-03614">105</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Other drugs</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Gabapentin (Calcium blocker) </td>
<td align="center" colspan="1" rowspan="1" valign="middle">Improvement [<xref ref-type="bibr" rid="B88-ijms-20-03614">88</xref>] </td>
<td align="center" colspan="1" rowspan="1" valign="middle">Relief of anxiety response [<xref ref-type="bibr" rid="B106-ijms-20-03614">106</xref>] </td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Prazosin (Alpha blocker) </td>
<td align="center" colspan="1" rowspan="1" valign="middle">Improvement [<xref ref-type="bibr" rid="B89-ijms-20-03614">89</xref>,<xref ref-type="bibr" rid="B90-ijms-20-03614">90</xref>], Not effective [<xref ref-type="bibr" rid="B91-ijms-20-03614">91</xref>] </td>
<td align="center" colspan="1" rowspan="1" valign="middle">Relief of fear response [<xref ref-type="bibr" rid="B107-ijms-20-03614">107</xref>], facilitation of fear extinction [<xref ref-type="bibr" rid="B108-ijms-20-03614">108</xref>] </td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Topiramate (Anticonvulsant) </td>
<td align="center" colspan="1" rowspan="1" valign="middle">Improvement [<xref ref-type="bibr" rid="B92-ijms-20-03614">92</xref>,<xref ref-type="bibr" rid="B93-ijms-20-03614">93</xref>] </td>
<td align="center" colspan="1" rowspan="1" valign="middle">Facilitation of fear extinction [<xref ref-type="bibr" rid="B109-ijms-20-03614">109</xref>] </td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Nabilone (Cannabinoid)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Improvement [<xref ref-type="bibr" rid="B94-ijms-20-03614">94</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">No data</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>